<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01272219</url>
  </required_header>
  <id_info>
    <org_study_id>NN8022-1839</org_study_id>
    <secondary_id>2008-001049-24</secondary_id>
    <secondary_id>U1111-1118-7871</secondary_id>
    <nct_id>NCT01272219</nct_id>
  </id_info>
  <brief_title>Effect of Liraglutide on Body Weight in Non-diabetic Obese Subjects or Overweight Subjects With Co-morbidities: SCALE™ - Obesity and Pre-diabetes</brief_title>
  <official_title>Effect of Liraglutide on Body Weight in Non-diabetic Obese Subjects or Overweight Subjects With Co-morbidities: A Randomised, Double-blind, Placebo Controlled, Parallel Group, Multi-centre, Multinational Trial With Stratification of Subject to Either 56 or 160 Weeks of Treatment Based on Pre-diabetes Status at Randomisation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novo Nordisk A/S</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novo Nordisk A/S</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This trial is conducted in Africa, Asia, Europe, Oceania, North America and South America.

      The aim of this clinical trial is to evaluate the potential of liraglutide to induce and
      maintain weight loss over 56 weeks in obese subjects or overweight subjects with
      co-morbidities. Furthermore, the aim is to investigate the long term potential of liraglutide
      to delay the onset of type 2 diabetes in subjects diagnosed with pre-diabetes at baseline.

      Based on body mass index (BMI) and pre-diabetes status, subjects will be randomised to either
      68 weeks (56 weeks of randomised treatment followed by a 12 week re-randomised treatment
      period) or 160 weeks of treatment (160 week treatment will only be applicable to subjects
      with pre-diabetes status at baseline).
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 1, 2011</start_date>
  <completion_date type="Actual">March 2, 2015</completion_date>
  <primary_completion_date type="Actual">March 18, 2013</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change From Baseline in Fasting Body Weight</measure>
    <time_frame>Week 0, Week 56</time_frame>
    <description>The observed mean change from baseline in fasting body weight (%) after 56-weeks of treatment (main treatment period).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Proportion of Subjects Losing at Least 5% of Baseline Fasting Body Weight.</measure>
    <time_frame>At Week 56</time_frame>
    <description>Percentage of subjects losing at least 5% of baseline fasting body weight after 56-weeks of treatment (main treatment period).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Proportion of Subjects Losing More Than 10% of Baseline Fasting Body Weight</measure>
    <time_frame>At 56 weeks</time_frame>
    <description>Percentage of subjects losing &gt;10% of baseline fasting body weight after 56-weeks of treatment (main treatment period).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Proportion of Subjects With Onset of Type 2 Diabetes</measure>
    <time_frame>At 160 weeks</time_frame>
    <description>Proportion of subjects with onset of Type 2 diabetes mellitus (T2DM) at week 160 (main + extension treatment period) among subjects with pre-diabetes at baseline - evaluated as time to onset of T2DM. Subjects included in FAS, who were stratified to 160-weeks of treatment (i.e., excluding 37 subjects with pre-diabetes who entered the re-randomised period and including 6 subjects without pre-diabetes incorrectly stratified to the 160-week treatment period).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Waist Circumference (cm)</measure>
    <time_frame>Week 0, Week 56</time_frame>
    <description>The observed mean change from baseline in waist circumference (cm) after 56-weeks of treatment (main treatment period).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Waist Circumference (Subjects With Pre-diabetes at Baseline)</measure>
    <time_frame>Week 0, week 160</time_frame>
    <description>The observed mean change from baseline in waist circumference (subjects with pre-diabetes at baseline) after 160 weeks of treatment (main + extension treatment period). Subjects included in FAS, who were stratified to 160-weeks of treatment (i.e., excluding 37 subjects with pre-diabetes who entered the re-randomised period and including 6 subjects without pre-diabetes incorrectly stratified to the 160-week treatment period).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pre-diabetes Status After 56 Weeks of Treatment</measure>
    <time_frame>Week 0, Week 56</time_frame>
    <description>Observed percentage of subjects with pre-diabetes status after 56 weeks of treatment (main treatment period).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pre-diabetes Status in Subject With Pre-diabetes at Baseline After 160 Weeks of Treatment</measure>
    <time_frame>Week 0, week 160</time_frame>
    <description>Observed percentage of subjects (subjects with pre-diabetes at baseline) with pre-diabetes status after 160 weeks of treatment (main + extension treatment period). Subjects included in FAS, who were stratified to 160-weeks of treatment (i.e., excluding 37 subjects with pre-diabetes who entered the re-randomised period and including 6 subjects without pre-diabetes incorrectly stratified to the 160-week treatment period).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline in Fasting Body Weight (Subjects With Pre-diabetes at Baseline)</measure>
    <time_frame>Week 0, week 160</time_frame>
    <description>The observed mean change from baseline in fasting body weight (subjects with pre-diabetes at baseline) after 160 weeks of treatment (main + extension treatment period). Subjects included in FAS, who were stratified to 160-weeks of treatment (i.e., excluding 37 subjects with pre-diabetes who entered the re-randomised period and including 6 subjects without pre-diabetes incorrectly stratified to the 160-week treatment period).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of Subjects Losing at Least 5% and Proportion of Subjects Losing More Than 10% of Baseline Fasting Body Weight (Subjects With Pre-diabetes at Baseline)</measure>
    <time_frame>At 160 weeks</time_frame>
    <description>Percentage of subjects losing &gt;=5% and percentage of subjects losing &gt;10% of baseline fasting body weight (pre-diabetic subjects at baseline) after 160-weeks of treatment (main + extension treatment period). Subjects included in FAS, who were stratified to 160-weeks of treatment (i.e., excluding 37 subjects with pre-diabetes who entered the re-randomised period and including 6 subjects without pre-diabetes incorrectly stratified to the 160-week treatment period).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Week 56 in Fasting Body Weight (%) (Re-randomised Subjects With No Pre-diabetes)</measure>
    <time_frame>Week 56, Week 68</time_frame>
    <description>The observed mean change in fasting body weight (%) from week 56 to week 68 in re-randomised subjects (with no pre-diabetes at baseline) after 12-weeks of treatment (re-randomised treatment period).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Fasting Body Weight (%) (Re-randomised Subjects With No Pre-diabetes)</measure>
    <time_frame>Week 0, Week 68</time_frame>
    <description>The observed mean change from baseline in fasting body weight (%) in re-randomised subjects (with no pre-diabetes at baseline) after 68 weeks of treatment (main + re-randomised treatment period).</description>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">3731</enrollment>
  <condition>Metabolism and Nutrition Disorder</condition>
  <condition>Obesity</condition>
  <arm_group>
    <arm_group_label>Liraglutide 3.0mg (week0-56)/Liraglutide 3.0mg (week56-68)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Liraglutide 3.0mg (week0-56)/Liraglutide Placebo (week56-68)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Liraglutide Placebo, no Pre-diabetes</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Liraglutide 3.0mg, Pre-diabetes</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Liraglutide Placebo, Pre-diabetes</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>liraglutide</intervention_name>
    <description>Subject with no pre-diabetes at screening, receiving liraglutide 3.0 mg subcutaneous (under the skin) injection once daily for 56 weeks. Subjects completing 56 weeks are re-randomised to receive liraglutide 3.0 mg for 12 weeks (until week 68).</description>
    <arm_group_label>Liraglutide 3.0mg (week0-56)/Liraglutide 3.0mg (week56-68)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>Subject with no pre-diabetes at screening, receiving liraglutide 3.0 mg subcutaneous (under the skin) injection once daily for 56 weeks. Subjects completing 56 weeks are re-randomised to receive liraglutide placebo for 12 weeks (until week 68).</description>
    <arm_group_label>Liraglutide 3.0mg (week0-56)/Liraglutide Placebo (week56-68)</arm_group_label>
    <arm_group_label>Liraglutide Placebo, no Pre-diabetes</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>liraglutide</intervention_name>
    <description>Liraglutide 3.0 mg, subcutaneous (under the skin) injection once daily for 160 weeks.</description>
    <arm_group_label>Liraglutide 3.0mg, Pre-diabetes</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>Liraglutide placebo, subcutaneous (under the skin) injection once daily for 160 weeks.</description>
    <arm_group_label>Liraglutide Placebo, Pre-diabetes</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Informed consent obtained

          -  Body Mass Index (BMI) of 30.0 kg/m^2 or above

          -  Body Mass Index (BMI) of 27 kg/m^2 or above in the presence of co-morbidities of
             treated or untreated dyslipidemia and/or hypertension

          -  Stable body weight

          -  Preceding failed dietary effort

        Exclusion Criteria:

          -  Known type 1 or type 2 diabetes

          -  Glycosylated haemoglobin (HbA1c) of 6.5 % or above (Screening visit 1) or FPG of 126
             mg/dL (7 mmol/L) or above (Screening visit 2) or 2 hour post-challenge (OGTT) plasma
             glucose of 200 mg/dL (11.1 mmol/L) or above (Screening visit 2)

          -  Screening calcitonin of 50 ng/L or above

          -  Family or personal history of multiple endocrine neoplasia type 2 (MEN2) or familial
             medullary thyroid carcinoma (FMTC)

          -  Personal history of non-familial medullary thyroid carcinoma

          -  History of acute or chronic pancreatitis

          -  Obesity induced by drug treatment

          -  Use of approved weight lowering pharmacotherapy

          -  Previous surgical treatment of obesity

          -  History of major depressive disorder or suicide attempt

          -  Uncontrolled hypertension (systolic blood pressure of 160 mmHg or above and/or
             diastolic blood pressure of 100 mmHg or above)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Global Clinical Registry GCR, 1452</last_name>
    <role>Study Director</role>
    <affiliation>Novo Nordisk A/S</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35205-4731</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85027</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Anaheim</city>
        <state>California</state>
        <zip>92801</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Concord</city>
        <state>California</state>
        <zip>94520</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Huntington Beach</city>
        <state>California</state>
        <zip>92646</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>La Jolla</city>
        <state>California</state>
        <zip>92037</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92103-4140</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92108</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Santa Monica</city>
        <state>California</state>
        <zip>90404</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Colorado Springs</city>
        <state>Colorado</state>
        <zip>80904</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Golden</city>
        <state>Colorado</state>
        <zip>80401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>New London</city>
        <state>Connecticut</state>
        <zip>06320</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Waterbury</city>
        <state>Connecticut</state>
        <zip>06708</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20036-5847</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Boynton Beach</city>
        <state>Florida</state>
        <zip>33437</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Bradenton</city>
        <state>Florida</state>
        <zip>34201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Crystal River</city>
        <state>Florida</state>
        <zip>34429</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Daytona Beach</city>
        <state>Florida</state>
        <zip>32117</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32216</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Ocala</city>
        <state>Florida</state>
        <zip>34471</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Ponte Vedra</city>
        <state>Florida</state>
        <zip>32081</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>South Miami</city>
        <state>Florida</state>
        <zip>33143</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Athens</city>
        <state>Georgia</state>
        <zip>30606</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Dunwoody</city>
        <state>Georgia</state>
        <zip>30338</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Sandy Springs</city>
        <state>Georgia</state>
        <zip>30328</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Suwanee</city>
        <state>Georgia</state>
        <zip>30024</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Aurora</city>
        <state>Illinois</state>
        <zip>60504</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Topeka</city>
        <state>Kansas</state>
        <zip>66606</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Baton Rouge</city>
        <state>Louisiana</state>
        <zip>70808-4124</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21209</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Elkridge</city>
        <state>Maryland</state>
        <zip>21075-6437</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>North Dartmouth</city>
        <state>Massachusetts</state>
        <zip>02747</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <zip>64111</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63141</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Saint Peters</city>
        <state>Missouri</state>
        <zip>63376</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10025</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14609</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Staten Island</city>
        <state>New York</state>
        <zip>10301</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Syracuse</city>
        <state>New York</state>
        <zip>13210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Cary</city>
        <state>North Carolina</state>
        <zip>27518</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Raleigh</city>
        <state>North Carolina</state>
        <zip>27612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Canal Fulton</city>
        <state>Ohio</state>
        <zip>44614</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45219</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Franklin</city>
        <state>Ohio</state>
        <zip>45005</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Wadsworth</city>
        <state>Ohio</state>
        <zip>44281-9236</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Tulsa</city>
        <state>Oklahoma</state>
        <zip>74136</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Eugene</city>
        <state>Oregon</state>
        <zip>97401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Beaver</city>
        <state>Pennsylvania</state>
        <zip>15009</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19107</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15206</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>West Reading</city>
        <state>Pennsylvania</state>
        <zip>19611</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29425</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Greer</city>
        <state>South Carolina</state>
        <zip>29651</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Bristol</city>
        <state>Tennessee</state>
        <zip>37620-7352</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78731</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75231</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75234</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75251</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75390-8858</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229-4801</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Sugar Land</city>
        <state>Texas</state>
        <zip>77479</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84107</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>West Jordan</city>
        <state>Utah</state>
        <zip>84088-8871</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Arlington</city>
        <state>Virginia</state>
        <zip>22206</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Henrico</city>
        <state>Virginia</state>
        <zip>23233</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23294</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Virginia Beach</city>
        <state>Virginia</state>
        <zip>23454</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Renton</city>
        <state>Washington</state>
        <zip>98057</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Wenatchee</city>
        <state>Washington</state>
        <zip>98801-2028</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <zip>53209</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Ciudad Autónoma de Bs As</city>
        <zip>C1426ABP</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Ciudad Autónoma de BsAs</city>
        <zip>C1406FWY</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Ciudad de Buenos Aires</city>
        <zip>C1405CWB</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Mar del Plata</city>
        <zip>B7600FZN</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>University Of Sydney</city>
        <state>New South Wales</state>
        <zip>2006</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Woolloongabba</city>
        <state>Queensland</state>
        <zip>4102</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Adelaide</city>
        <state>South Australia</state>
        <zip>5005</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Heidelberg West</city>
        <state>Victoria</state>
        <zip>3081</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Graz</city>
        <zip>8036</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Salzburg</city>
        <zip>5020</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Wien</city>
        <zip>1090</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Wien</city>
        <zip>1130</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Boussu</city>
        <zip>7300</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Edegem</city>
        <zip>2650</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Liège</city>
        <zip>4000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Porto Alegre</city>
        <state>Rio Grande Do Sul</state>
        <zip>90035-170</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Campinas</city>
        <state>Sao Paulo</state>
        <zip>13073-350</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>São Paulo</city>
        <state>Sao Paulo</state>
        <zip>05403-000</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Curitiba</city>
        <zip>80030-110</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>São Paulo</city>
        <zip>04022-002</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Calgary</city>
        <state>Alberta</state>
        <zip>T2T 5C7</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Edmonton</city>
        <state>Alberta</state>
        <zip>T6G 2E1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Mount Pearl</city>
        <state>Newfoundland and Labrador</state>
        <zip>A1N 1W7</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>St. John's</city>
        <state>Newfoundland and Labrador</state>
        <zip>A1A 3R5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Halifax</city>
        <state>Nova Scotia</state>
        <zip>B3H 2Y9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Cambridge</city>
        <state>Ontario</state>
        <zip>N1R 7L6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <zip>L8L 2X2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <zip>L8M 1K7</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Ottawa</city>
        <state>Ontario</state>
        <zip>K1H 1A2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Pointe Claire</city>
        <state>Quebec</state>
        <zip>H9R 4S3</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Quebec</city>
        <zip>G1V 4G2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Quebec</city>
        <zip>G1V 4G5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Frederiksberg C</city>
        <zip>1958</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Hvidovre</city>
        <zip>2650</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Århus C</city>
        <zip>8000</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Kuopio</city>
        <zip>07100</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Oulu</city>
        <zip>90220</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>University Of Helsinki</city>
        <zip>00014</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Belgrade</city>
        <zip>11000</zip>
        <country>Former Serbia and Montenegro</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Antibes</city>
        <zip>06600</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Lille</city>
        <zip>59037</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>PARIS cedex 13</city>
        <zip>75651</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Paris</city>
        <zip>75877</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Pierre-Bénite</city>
        <zip>69495</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Saint Herblain</city>
        <zip>44800</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Bad Nauheim</city>
        <zip>61231</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Berlin</city>
        <zip>13055</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Dresden</city>
        <zip>01219</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Duisburg</city>
        <zip>47051</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Freiburg</city>
        <zip>79106</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Giessen</city>
        <zip>35392</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Gifhorn</city>
        <zip>38518</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Leipzig</city>
        <zip>04103</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Mannheim</city>
        <zip>68163</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Saint Ingbert</city>
        <zip>66386</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Shatin, New Territories</city>
        <country>Hong Kong</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Budapest</city>
        <zip>H-1115</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Budapest</city>
        <zip>H-1134</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Debrecen</city>
        <zip>H-4012</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Bangalore</city>
        <state>Karnataka</state>
        <zip>560 017</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Belgaum</city>
        <state>Karnataka</state>
        <zip>590001</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Mumbai</city>
        <state>Maharashtra</state>
        <zip>4000021</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Mumbai</city>
        <state>Maharashtra</state>
        <zip>400007</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Mumbai</city>
        <state>Maharashtra</state>
        <zip>400703</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Pune</city>
        <state>Maharashtra</state>
        <zip>411030</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Trichy</city>
        <state>Tamil Nadu</state>
        <zip>620018</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Karnal</city>
        <zip>132001</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Kerala</city>
        <zip>682026</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Dublin 9</city>
        <country>Ireland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Dublin</city>
        <zip>DUBLIN 4</zip>
        <country>Ireland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Dublin</city>
        <zip>DUBLIN 8</zip>
        <country>Ireland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Galway</city>
        <zip>H91 YR71</zip>
        <country>Ireland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Haifa</city>
        <zip>31096</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Jerusalem</city>
        <zip>91120</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Kfar Saba</city>
        <zip>44281</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Ofakim</city>
        <zip>87520</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Petah-Tikva</city>
        <zip>49100</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Petah-Tikva</city>
        <zip>49372</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Tel Hashomer</city>
        <zip>52621</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Tel-Aviv</city>
        <zip>64239</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Bologna</city>
        <zip>40138</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Firenze</city>
        <zip>50139</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Milano</city>
        <zip>20145</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Padova</city>
        <zip>35128</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Palermo</city>
        <zip>90127</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Pisa</city>
        <zip>56124</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Roma</city>
        <zip>00168</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Siena</city>
        <zip>53100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Pachuca</city>
        <state>Hidalgo</state>
        <zip>42084</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Guadalajara</city>
        <state>Jalisco</state>
        <zip>44600</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Guadalajara</city>
        <state>Jalisco</state>
        <zip>44650</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Mexico City</city>
        <state>México, D.F.</state>
        <zip>03300</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Mexico City</city>
        <state>México, D.F.</state>
        <zip>14000</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Tampico</city>
        <state>Tamaulipas</state>
        <zip>89000</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Durango</city>
        <zip>34000</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Monterrey</city>
        <zip>64700</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Almere</city>
        <zip>1311RL</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Amsterdam</city>
        <zip>1066 EC</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Beek</city>
        <zip>6191JW</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Hengelo OV</city>
        <zip>7555 DL</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Hilversum</city>
        <zip>1213 RH</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Leidschendam</city>
        <zip>2262 BA</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Zwijndrecht</city>
        <zip>3331 LZ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Bergen</city>
        <zip>NO-5012</zip>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Oslo</city>
        <zip>0424</zip>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Trondheim</city>
        <zip>7030</zip>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Tønsberg</city>
        <zip>3117</zip>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Bialystok</city>
        <zip>15-381</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Katowice</city>
        <zip>40-662</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Katowice</city>
        <zip>40-767</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Poznan</city>
        <zip>60-569</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Szczecin</city>
        <zip>70-483</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Szczecin</city>
        <zip>71-455</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Warszawa</city>
        <zip>02-507</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Arkhangelsk</city>
        <zip>163045</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Moscow</city>
        <zip>101990</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Moscow</city>
        <zip>115093</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Moscow</city>
        <zip>117036</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Moscow</city>
        <zip>121356</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Moscow</city>
        <zip>125367</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Moscow</city>
        <zip>127486</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Novosibirsk</city>
        <zip>630047</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Tumen</city>
        <zip>625023</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Belgrade</city>
        <zip>11000</zip>
        <country>Serbia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Johannesburg</city>
        <state>Gauteng</state>
        <zip>2193</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Pretoria</city>
        <state>Gauteng</state>
        <zip>0083</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Cape Town</city>
        <state>Western Cape</state>
        <zip>7130</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Almería</city>
        <zip>04001</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Barcelona</city>
        <zip>08036</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Madrid</city>
        <zip>28006</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Santiago de Compostela</city>
        <zip>15706</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Sevilla</city>
        <zip>41003</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Valladolid</city>
        <zip>47005</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Baden-Dättwil</city>
        <zip>5405</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Bern</city>
        <zip>3010</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Genève 14</city>
        <zip>1211</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>St. Gallen</city>
        <zip>9016</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Zollikerberg</city>
        <zip>8125</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Ankara</city>
        <zip>06100</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Ankara</city>
        <zip>06110</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Istanbul</city>
        <zip>34098</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Istanbul</city>
        <zip>34371</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Istanbul</city>
        <zip>34668</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Istanbul</city>
        <zip>34760</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Coventry</city>
        <zip>CV2 2DX</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Glasgow</city>
        <zip>G11 6NT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Hull</city>
        <zip>HU3 2RW</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Liverpool</city>
        <zip>L9 7AL</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>London</city>
        <zip>SE1 9RT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>London</city>
        <zip>W1T 7DN</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>London</city>
        <zip>W6 8RF</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Luton</city>
        <zip>LU4 0DZ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Swansea</city>
        <zip>SA6 6NL</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Argentina</country>
    <country>Australia</country>
    <country>Austria</country>
    <country>Belgium</country>
    <country>Brazil</country>
    <country>Canada</country>
    <country>Denmark</country>
    <country>Finland</country>
    <country>Former Serbia and Montenegro</country>
    <country>France</country>
    <country>Germany</country>
    <country>Hong Kong</country>
    <country>Hungary</country>
    <country>India</country>
    <country>Ireland</country>
    <country>Israel</country>
    <country>Italy</country>
    <country>Mexico</country>
    <country>Netherlands</country>
    <country>Norway</country>
    <country>Poland</country>
    <country>Russian Federation</country>
    <country>Serbia</country>
    <country>South Africa</country>
    <country>Spain</country>
    <country>Switzerland</country>
    <country>Turkey</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://novonordisk-trials.com</url>
    <description>Clinical Trials at Novo Nordisk</description>
  </link>
  <results_reference>
    <citation>Kolotkin RL, Fujioka K, Wolden ML, Brett JH, Bjorner JB. Improvements in health-related quality of life with liraglutide 3.0 mg compared with placebo in weight management. Clin Obes. 2016 Aug;6(4):233-42. doi: 10.1111/cob.12146. Epub 2016 May 19.</citation>
    <PMID>27198973</PMID>
  </results_reference>
  <results_reference>
    <citation>Overgaard RV, Petri KC, Jacobsen LV, Jensen CB. Liraglutide 3.0 mg for Weight Management: A Population Pharmacokinetic Analysis. Clin Pharmacokinet. 2016 Nov;55(11):1413-1422.</citation>
    <PMID>27193270</PMID>
  </results_reference>
  <results_reference>
    <citation>O'Neil PM, Garvey WT, Gonzalez-Campoy JM, Mora P, Ortiz RV, Guerrero G, Claudius B, Pi-Sunyer X; Satiety and Clinical Adiposity – Liraglutide Evidence in individuals with and without diabetes (SCALE) study groups. EFFECTS OF LIRAGLUTIDE 3.0 MG ON WEIGHT AND RISK FACTORS IN HISPANIC VERSUS NON-HIPANIC POPULATIONS: SUBGROUP ANALYSIS FROM SCALE RANDOMIZED TRIALS. Endocr Pract. 2016 Nov;22(11):1277-1287. Epub 2016 Aug 2.</citation>
    <PMID>27482610</PMID>
  </results_reference>
  <results_reference>
    <citation>Fujioka K, O'Neil PM, Davies M, Greenway F, C W Lau D, Claudius B, Skjøth TV, Bjørn Jensen C, P H Wilding J. Early Weight Loss with Liraglutide 3.0 mg Predicts 1-Year Weight Loss and is Associated with Improvements in Clinical Markers. Obesity (Silver Spring). 2016 Nov;24(11):2278-2288. doi: 10.1002/oby.21629.</citation>
    <PMID>27804269</PMID>
  </results_reference>
  <results_reference>
    <citation>Bays H, Pi-Sunyer X, Hemmingsson JU, Claudius B, Jensen CB, Van Gaal L. Liraglutide 3.0 mg for weight management: weight-loss dependent and independent effects. Curr Med Res Opin. 2017 Feb;33(2):225-229. doi: 10.1080/03007995.2016.1251892. Epub 2016 Nov 6.</citation>
    <PMID>27817208</PMID>
  </results_reference>
  <results_reference>
    <citation>Wilding JP, Overgaard RV, Jacobsen LV, Jensen CB, le Roux CW. Exposure-response analyses of liraglutide 3.0 mg for weight management. Diabetes Obes Metab. 2016 May;18(5):491-9. doi: 10.1111/dom.12639. Epub 2016 Mar 1.</citation>
    <PMID>26833744</PMID>
  </results_reference>
  <results_reference>
    <citation>Pi-Sunyer X, Astrup A, Fujioka K, Greenway F, Halpern A, Krempf M, Lau DC, le Roux CW, Violante Ortiz R, Jensen CB, Wilding JP; SCALE Obesity and Prediabetes NN8022-1839 Study Group. A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management. N Engl J Med. 2015 Jul 2;373(1):11-22. doi: 10.1056/NEJMoa1411892.</citation>
    <PMID>26132939</PMID>
  </results_reference>
  <results_reference>
    <citation>McEvoy BW. Missing data in clinical trials for weight management. J Biopharm Stat. 2016;26(1):30-6. doi: 10.1080/10543406.2015.1094814. Review.</citation>
    <PMID>26418188</PMID>
  </results_reference>
  <results_reference>
    <citation>Ard J, Cannon A, Lewis CE, Lofton H, Vang Skjøth T, Stevenin B, Pi-Sunyer X. Efficacy and safety of liraglutide 3.0 mg for weight management are similar across races: subgroup analysis across the SCALE and phase II randomized trials. Diabetes Obes Metab. 2016 Apr;18(4):430-5. doi: 10.1111/dom.12632. Epub 2016 Feb 11.</citation>
    <PMID>26744025</PMID>
  </results_reference>
  <results_reference>
    <citation>le Roux CW, Astrup A, Fujioka K, Greenway F, Lau DCW, Van Gaal L, Ortiz RV, Wilding JPH, Skjøth TV, Manning LS, Pi-Sunyer X; SCALE Obesity Prediabetes NN8022-1839 Study Group. 3 years of liraglutide versus placebo for type 2 diabetes risk reduction and weight management in individuals with prediabetes: a randomised, double-blind trial. Lancet. 2017 Apr 8;389(10077):1399-1409. doi: 10.1016/S0140-6736(17)30069-7. Epub 2017 Feb 23. Erratum in: Lancet. 2017 Apr 8;389(10077):1398.</citation>
    <PMID>28237263</PMID>
  </results_reference>
  <results_reference>
    <citation>von Scholten BJ, Davies MJ, Persson F, Hansen TW, Madsbad S, Endahl L, Jepsen CH, Rossing P. Effect of weight reductions on estimated kidney function: Post-hoc analysis of two randomized trials. J Diabetes Complications. 2017 Jul;31(7):1164-1168. doi: 10.1016/j.jdiacomp.2017.04.003. Epub 2017 Apr 11.</citation>
    <PMID>28462892</PMID>
  </results_reference>
  <results_reference>
    <citation>O'Neil PM, Aroda VR, Astrup A, Kushner R, Lau DCW, Wadden TA, Brett J, Cancino AP, Wilding JPH; Satiety and Clinical Adiposity - Liraglutide Evidence in individuals with and without diabetes (SCALE) study groups. Neuropsychiatric safety with liraglutide 3.0 mg for weight management: Results from randomized controlled phase 2 and 3a trials. Diabetes Obes Metab. 2017 Nov;19(11):1529-1536. doi: 10.1111/dom.12963. Epub 2017 Jul 21.</citation>
    <PMID>28386912</PMID>
  </results_reference>
  <results_reference>
    <citation>Davies MJ, Aronne LJ, Caterson ID, Thomsen AB, Jacobsen PB, Marso SP; Satiety and Clinical Adiposity - Liraglutide Evidence in individuals with and without diabetes (SCALE) study groups. Liraglutide and cardiovascular outcomes in adults with overweight or obesity: A post hoc analysis from SCALE randomized controlled trials. Diabetes Obes Metab. 2018 Mar;20(3):734-739. doi: 10.1111/dom.13125. Epub 2017 Nov 1.</citation>
    <PMID>28950422</PMID>
  </results_reference>
  <results_reference>
    <citation>Kolotkin RL, Gabriel Smolarz B, Meincke HH, Fujioka K. Improvements in health-related quality of life over 3 years with liraglutide 3.0 mg compared with placebo in participants with overweight or obesity. Clin Obes. 2018 Feb;8(1):1-10. doi: 10.1111/cob.12226. Epub 2017 Oct 16.</citation>
    <PMID>29045079</PMID>
  </results_reference>
  <results_reference>
    <citation>le Roux C, Aroda V, Hemmingsson J, Cancino AP, Christensen R, Pi-Sunyer X. Comparison of Efficacy and Safety of Liraglutide 3.0 mg in Individuals with BMI above and below 35 kg/m²: A Post-hoc Analysis. Obes Facts. 2017;10(6):531-544. doi: 10.1159/000478099. Epub 2017 Nov 17.</citation>
    <PMID>29145215</PMID>
  </results_reference>
  <verification_date>December 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 6, 2011</study_first_submitted>
  <study_first_submitted_qc>January 6, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 7, 2011</study_first_posted>
  <results_first_submitted>January 22, 2015</results_first_submitted>
  <results_first_submitted_qc>January 22, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">February 9, 2015</results_first_posted>
  <disposition_first_submitted>March 4, 2014</disposition_first_submitted>
  <disposition_first_submitted_qc>March 12, 2014</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">April 9, 2014</disposition_first_posted>
  <last_update_submitted>December 20, 2017</last_update_submitted>
  <last_update_submitted_qc>December 20, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">January 19, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Obesity</mesh_term>
    <mesh_term>Overweight</mesh_term>
    <mesh_term>Body Weight</mesh_term>
    <mesh_term>Prediabetic State</mesh_term>
    <mesh_term>Glucose Intolerance</mesh_term>
    <mesh_term>Nutrition Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liraglutide</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>The trial was conducted at 191 sites in 27 countries: Australia:4,Austria:3,Belgium:2, Brazil:5,Canada:11, Denmark:3,Finland:3, France:5, Germany:8,Hong Kong:1, Hungary:2, India:8, Ireland:1,Israel:7, Italy:7, Mexico:4, Netherlands:5, Norway:3, Poland:5, Russian:7, Serbia:2, South Africa:3, Spain:6, Switzerland:5,Turkey:4, UK:8, US:69.</recruitment_details>
      <pre_assignment_details>Subjects were stratified based on pre-diabetes status and BMI at screening. The Main Period table, below, reflects the stratification that should have occurred at baseline. The Re-randomized Period and Main + Extension Period tables reflect the actual distribution of subjects, factoring in an incorrect stratification of 43 subjects at screening.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Liraglutide 3.0 mg, no Pre-diabetes</title>
          <description>Arm 1 (Arm 1A + Arm 1B): Subjects with no pre-diabetes at screening received liraglutide 3.0 mg, once daily (OD) subcutaneously (s.c. injection, under the skin) for 56 weeks followed by a re-randomisation (1:1 into liraglutide 3.0 mg or liraglutide placebo) period of 12 weeks (weeks 56-68) and then an off-drug follow-up period of 2 weeks. The total duration of this treatment arm from randomisation to follow-up was 70 weeks.</description>
        </group>
        <group group_id="P2">
          <title>Liraglutide 3.0mg (week0-56)/Liraglutide 3.0mg (week56-68)</title>
          <description>Arm 1A: Subjects of Arm 1 (with no pre-diabetes at screening) receiving liraglutide 3.0 mg, once daily (OD) subcutaneously (s.c. injection, under the skin) for 56 weeks were re-randomised (1:1 into liraglutide 3.0 mg or liraglutide placebo) to continue treatment with liraglutide 3.0 mg for the next 12 weeks (weeks 56-68), followed by a 2 weeks off-drug follow-up period.</description>
        </group>
        <group group_id="P3">
          <title>Liraglutide 3.0mg (week0-56)/Liraglutide Placebo (week56-68)</title>
          <description>Arm 1B: Subjects of Arm 1 (with no pre-diabetes at screening) receiving liraglutide 3.0 mg, once daily (OD) subcutaneously (s.c. injection, under the skin) for 56 weeks were re-randomised (1:1 into liraglutide 3.0 mg or liraglutide placebo) to receive liraglutide placebo for the next 12 weeks (weeks 56-68), followed by a 2 weeks off-drug follow-up period.</description>
        </group>
        <group group_id="P4">
          <title>Liraglutide Placebo, no Pre-diabetes</title>
          <description>Arm 2: Subjects with no pre-diabetes at screening received liraglutide placebo once daily (OD) subcutaneously (s.c. injection, under the skin) for 56 weeks and then continued with liraglutide placebo for additional 12 weeks (weeks 56-68), followed by a 2 weeks off-drug follow-up period. The total duration of this treatment arm from randomisation to follow-up was 70 weeks.</description>
        </group>
        <group group_id="P5">
          <title>Liraglutide 3.0 mg, Pre-diabetes</title>
          <description>Arm 3: Subjects with pre-diabetes at screening received liraglutide 3.0 mg, once daily (OD) subcutaneously (s.c. injection, under the skin) for initial 56 weeks then continued treatment till 160 weeks, followed by an off-drug, observational follow-up period of 12 weeks. The total duration of this treatment arm from randomisation to follow-up was 172 weeks.</description>
        </group>
        <group group_id="P6">
          <title>Liraglutide Placebo, Pre-diabetes</title>
          <description>Arm 4: Subjects with pre-diabetes at screening received liraglutide placebo once daily (OD) subcutaneously (s.c. injection, under the skin) for initial 56 weeks then continued treatment till 160 weeks, followed by an off-drug, observational follow-up period of 12 weeks. The total duration of this treatment arm from randomisation to follow-up was 172 weeks.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Main Period: Week 0 to Week 56</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="959"/>
                <participants group_id="P2" count="0">This arm is not considered for main period as these subjects belong to re-randomised period</participants>
                <participants group_id="P3" count="0">This arm is not considered for main period as these subjects belong to re-randomised period</participants>
                <participants group_id="P4" count="487"/>
                <participants group_id="P5" count="1528"/>
                <participants group_id="P6" count="757"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Exposed</title>
              <participants_list>
                <participants group_id="P1" count="957"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="487"/>
                <participants group_id="P5" count="1524"/>
                <participants group_id="P6" count="755"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="679"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="296"/>
                <participants group_id="P5" count="1110"/>
                <participants group_id="P6" count="505"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="280"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="191"/>
                <participants group_id="P5" count="418"/>
                <participants group_id="P6" count="252"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="86"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="16"/>
                <participants group_id="P5" count="152"/>
                <participants group_id="P6" count="29"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="14"/>
                <participants group_id="P5" count="12"/>
                <participants group_id="P6" count="22"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="25"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="18"/>
                <participants group_id="P5" count="40"/>
                <participants group_id="P6" count="20"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal criteria</title>
              <participants_list>
                <participants group_id="P1" count="122"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="114"/>
                <participants group_id="P5" count="172"/>
                <participants group_id="P6" count="147"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Unclassified</title>
              <participants_list>
                <participants group_id="P1" count="36"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="29"/>
                <participants group_id="P5" count="42"/>
                <participants group_id="P6" count="34"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Re-randomised Period: Week 56 to Week 68</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="0">This arm is not considered for re-randomised period as these subjects belong to main period</participants>
                <participants group_id="P2" count="351">Incorrect stratification: In this period, overall 37 pre-diabetic subjects were included by error.</participants>
                <participants group_id="P3" count="350">Incorrect stratification: In this period, overall 37 pre-diabetic subjects were included by error.</participants>
                <participants group_id="P4" count="304">Incorrect stratification: In this period, overall 37 pre-diabetic subjects were included by error.</participants>
                <participants group_id="P5" count="0">This arm is not considered for re-randomised period as these subjects belong to main period</participants>
                <participants group_id="P6" count="0">This arm is not considered for re-randomised period as these subjects belong to main period</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="342"/>
                <participants group_id="P3" count="343"/>
                <participants group_id="P4" count="289"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="9"/>
                <participants group_id="P3" count="7"/>
                <participants group_id="P4" count="15"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="2"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="3"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal criteria</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="4"/>
                <participants group_id="P4" count="7"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Unclassified</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="2"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Main + Extension Period: Week 0-172</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="0">This arm is not considered for this period as these subjects belong to main period</participants>
                <participants group_id="P2" count="0">This arm is not considered for this period as these subjects belong to re-randomised period</participants>
                <participants group_id="P3" count="0">This arm is not considered for this period as these subjects belong to re-randomised period</participants>
                <participants group_id="P4" count="0">This arm is not considered for this period as these subjects belong to main and re-randomised period</participants>
                <participants group_id="P5" count="1505">Incorrect stratification: In this period, overall 6 subjects with no pre-diabetes included by error.</participants>
                <participants group_id="P6" count="749">Incorrect stratification: In this period, overall 6 subjects with no pre-diabetes included by error.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>Exposed</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="1501"/>
                <participants group_id="P6" count="747"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="783"/>
                <participants group_id="P6" count="327"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="722"/>
                <participants group_id="P6" count="422"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="191"/>
                <participants group_id="P6" count="43"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="29"/>
                <participants group_id="P6" count="36"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="76"/>
                <participants group_id="P6" count="36"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal criteria</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="364"/>
                <participants group_id="P6" count="256"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Missing reason</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Unclassified</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="61"/>
                <participants group_id="P6" count="51"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Liraglutide 3.0 mg, no Pre-diabetes</title>
          <description>Arm 1 (Arm 1A + Arm 1B): Subjects with no pre-diabetes at screening received liraglutide 3.0 mg, once daily (OD) subcutaneously (s.c. injection, under the skin) for 56 weeks followed by a re-randomisation (1:1 into liraglutide 3.0 mg or liraglutide placebo) period of 12 weeks (weeks 56-68) and then an off-drug follow-up period of 2 weeks. The total duration of this treatment arm from randomisation to follow-up was 70 weeks.</description>
        </group>
        <group group_id="B2">
          <title>Liraglutide Placebo, no Pre-diabetes</title>
          <description>Arm 2: Subjects with no pre-diabetes at screening received liraglutide placebo once daily (OD) subcutaneously (s.c. injection, under the skin) for 56 weeks and then continued with liraglutide placebo for additional 12 weeks (weeks 56-68), followed by a 2 weeks off-drug follow-up period. The total duration of this treatment arm from randomisation to follow-up was 70 weeks.</description>
        </group>
        <group group_id="B3">
          <title>Liraglutide 3.0 mg, Pre-diabetes</title>
          <description>Arm 3: Subjects with pre-diabetes at screening received liraglutide 3.0 mg, once daily (OD) subcutaneously (s.c. injection, under the skin) for initial 56 weeks then continued treatment till 160 weeks, followed by an off-drug, observational follow-up period of 12 weeks. The total duration of this treatment arm from randomisation to follow-up was 172 weeks.</description>
        </group>
        <group group_id="B4">
          <title>Liraglutide Placebo, Pre-diabetes</title>
          <description>Arm 4: Subjects with pre-diabetes at screening received liraglutide placebo once daily (OD) subcutaneously (s.c. injection, under the skin) for initial 56 weeks then continued treatment till 160 weeks, followed by an off-drug, observational follow-up period of 12 weeks. The total duration of this treatment arm from randomisation to follow-up was 172 weeks.</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="959"/>
            <count group_id="B2" value="487"/>
            <count group_id="B3" value="1528"/>
            <count group_id="B4" value="757"/>
            <count group_id="B5" value="3731"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="41.6" spread="11.7"/>
                    <measurement group_id="B2" value="41.5" spread="11.5"/>
                    <measurement group_id="B3" value="47.4" spread="11.8"/>
                    <measurement group_id="B4" value="47.2" spread="11.8"/>
                    <measurement group_id="B5" value="45.1" spread="12.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="801"/>
                    <measurement group_id="B2" value="390"/>
                    <measurement group_id="B3" value="1156"/>
                    <measurement group_id="B4" value="581"/>
                    <measurement group_id="B5" value="2928"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="158"/>
                    <measurement group_id="B2" value="97"/>
                    <measurement group_id="B3" value="372"/>
                    <measurement group_id="B4" value="176"/>
                    <measurement group_id="B5" value="803"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Fasting Body Weight</title>
          <units>kg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="104.0" spread="20.1"/>
                    <measurement group_id="B2" value="103.6" spread="21.2"/>
                    <measurement group_id="B3" value="107.6" spread="21.8"/>
                    <measurement group_id="B4" value="107.9" spread="21.8"/>
                    <measurement group_id="B5" value="106.2" spread="21.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Body Mass Index (BMI)</title>
          <units>kg/m^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="37.5" spread="6.2"/>
                    <measurement group_id="B2" value="37.4" spread="6.2"/>
                    <measurement group_id="B3" value="38.8" spread="6.4"/>
                    <measurement group_id="B4" value="39.0" spread="6.3"/>
                    <measurement group_id="B5" value="38.3" spread="6.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Glycosylated Haemoglobin (HbA1c)</title>
          <units>percentage of glycosylated haemoglobin</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5.3" spread="0.3"/>
                    <measurement group_id="B2" value="5.3" spread="0.3"/>
                    <measurement group_id="B3" value="5.8" spread="0.3"/>
                    <measurement group_id="B4" value="5.7" spread="0.3"/>
                    <measurement group_id="B5" value="5.6" spread="0.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Fasting Plasma Glucose (FPG)</title>
          <units>mmol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5.0" spread="0.4"/>
                    <measurement group_id="B2" value="5.1" spread="0.5"/>
                    <measurement group_id="B3" value="5.5" spread="0.6"/>
                    <measurement group_id="B4" value="5.5" spread="0.5"/>
                    <measurement group_id="B5" value="5.3" spread="0.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Fasting Body Weight</title>
        <description>The observed mean change from baseline in fasting body weight (%) after 56-weeks of treatment (main treatment period).</description>
        <time_frame>Week 0, Week 56</time_frame>
        <population>The full analysis set (FAS) included all randomised subjects who were exposed to at least one dose of trial product (liraglutide 3.0 mg or liraglutide placebo) and who provided at least one post-baseline efficacy value. Missing data were imputed using last observation carried forward (LOCF).</population>
        <group_list>
          <group group_id="O1">
            <title>Liraglutide 3.0 mg (56-Week)</title>
            <description>Subjects belong to Arm 1 (with no pre-diabetes at screening) and Arm 3 (with pre-diabetes at screening), received liraglutide 3.0 mg, once daily (OD) subcutaneously (s.c. injection, under the skin) for 56 weeks, from randomisation.</description>
          </group>
          <group group_id="O2">
            <title>Liraglutide Placebo (56-Week)</title>
            <description>Subjects belong to Arm 2 (with no pre-diabetes at screening) and Arm 4 (with pre-diabetes at screening), received liraglutide Placebo, once daily (OD) subcutaneously (s.c. injection, under the skin) for 56 weeks, from randomisation.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Fasting Body Weight</title>
          <description>The observed mean change from baseline in fasting body weight (%) after 56-weeks of treatment (main treatment period).</description>
          <population>The full analysis set (FAS) included all randomised subjects who were exposed to at least one dose of trial product (liraglutide 3.0 mg or liraglutide placebo) and who provided at least one post-baseline efficacy value. Missing data were imputed using last observation carried forward (LOCF).</population>
          <units>percent change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2432"/>
                <count group_id="O2" value="1220"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-7.98" spread="6.67"/>
                    <measurement group_id="O2" value="-2.62" spread="5.74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Null-hypothesis: no treatment difference between treatment arms, i.e. liraglutide 3.0 mg and liraglutide placebo. Liraglutide 3.0 mg was considered superior to placebo in inducing and maintaining weight loss, if the estimated treatment effect (liraglutide 3.0 mg – liraglutide placebo) was statistically significantly smaller than zero.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA</method>
            <param_type>Estimated mean difference</param_type>
            <param_value>-5.39</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-5.82</ci_lower_limit>
            <ci_upper_limit>-4.95</ci_upper_limit>
            <estimate_desc>ANCOVA model with treatment, country, sex, pre-diabetes status at screening, baseline BMI stratum and an interaction between pre-diabetes status at screening and BMI stratum as fixed factors, and the baseline value as covariate.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Proportion of Subjects Losing at Least 5% of Baseline Fasting Body Weight.</title>
        <description>Percentage of subjects losing at least 5% of baseline fasting body weight after 56-weeks of treatment (main treatment period).</description>
        <time_frame>At Week 56</time_frame>
        <population>The FAS included all randomised subjects who were exposed to at least one dose of trial product (liraglutide 3.0 mg or liraglutide placebo) and who provided at least one post-baseline efficacy value. Missing data were imputed using LOCF.</population>
        <group_list>
          <group group_id="O1">
            <title>Liraglutide 3.0 mg (56-Week)</title>
            <description>Subjects belong to Arm 1 (with no pre-diabetes at screening) and Arm 3 (with pre-diabetes at screening), received liraglutide 3.0 mg, once daily (OD) subcutaneously (s.c. injection, under the skin) for 56 weeks, from randomisation.</description>
          </group>
          <group group_id="O2">
            <title>Liraglutide Placebo (56-Week)</title>
            <description>Subjects belong to Arm 2 (with no pre-diabetes at screening) and Arm 4 (with pre-diabetes at screening), received liraglutide Placebo, once daily (OD) subcutaneously (s.c. injection, under the skin) for 56 weeks, from randomisation.</description>
          </group>
        </group_list>
        <measure>
          <title>Proportion of Subjects Losing at Least 5% of Baseline Fasting Body Weight.</title>
          <description>Percentage of subjects losing at least 5% of baseline fasting body weight after 56-weeks of treatment (main treatment period).</description>
          <population>The FAS included all randomised subjects who were exposed to at least one dose of trial product (liraglutide 3.0 mg or liraglutide placebo) and who provided at least one post-baseline efficacy value. Missing data were imputed using LOCF.</population>
          <units>percentage of subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2432"/>
                <count group_id="O2" value="1220"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="63.2"/>
                    <measurement group_id="O2" value="27.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Null-hypothesis: no treatment difference between treatment arms, i.e. liraglutide 3.0 mg and liraglutide placebo. Liraglutide 3.0 mg was considered superior to placebo in inducing and maintaining weight loss as assessed by the proportion of subjects losing ≥5% of their fasting baseline weight, if the estimated odds ratio (liraglutide 3.0 mg/liraglutide placebo) was statistically significantly greater than one.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>4.80</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>4.12</ci_lower_limit>
            <ci_upper_limit>5.60</ci_upper_limit>
            <estimate_desc>The model included treatment, country, sex, pre-diabetes status at screening, BMI stratum and an interaction between pre-diabetes status at screening and BMI stratum as fixed factors, and the baseline value as covariate.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Proportion of Subjects Losing More Than 10% of Baseline Fasting Body Weight</title>
        <description>Percentage of subjects losing &gt;10% of baseline fasting body weight after 56-weeks of treatment (main treatment period).</description>
        <time_frame>At 56 weeks</time_frame>
        <population>The FAS) included all randomised subjects who were exposed to at least one dose of trial product (liraglutide 3.0 mg or liraglutide placebo) and who provided at least one post-baseline efficacy value. Missing data were imputed using LOCF.</population>
        <group_list>
          <group group_id="O1">
            <title>Liraglutide 3.0 mg (56-Week)</title>
            <description>Subjects belong to Arm 1 (with no pre-diabetes at screening) and Arm 3 (with pre-diabetes at screening), received liraglutide 3.0 mg, once daily (OD) subcutaneously (s.c. injection, under the skin) for 56 weeks, from randomisation.</description>
          </group>
          <group group_id="O2">
            <title>Liraglutide Placebo (56-Week)</title>
            <description>Subjects belong to Arm 2 (with no pre-diabetes at screening) and Arm 4 (with pre-diabetes at screening), received liraglutide Placebo, once daily (OD) subcutaneously (s.c. injection, under the skin) for 56 weeks, from randomisation.</description>
          </group>
        </group_list>
        <measure>
          <title>Proportion of Subjects Losing More Than 10% of Baseline Fasting Body Weight</title>
          <description>Percentage of subjects losing &gt;10% of baseline fasting body weight after 56-weeks of treatment (main treatment period).</description>
          <population>The FAS) included all randomised subjects who were exposed to at least one dose of trial product (liraglutide 3.0 mg or liraglutide placebo) and who provided at least one post-baseline efficacy value. Missing data were imputed using LOCF.</population>
          <units>percentage of subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2432"/>
                <count group_id="O2" value="1220"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33.1"/>
                    <measurement group_id="O2" value="10.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Null-hypothesis: no treatment difference between treatment arms, i.e. liraglutide 3.0 mg and liraglutide placebo. Liraglutide 3.0 mg was considered superior to placebo in inducing and maintaining weight loss as assessed by the proportion of subjects losing &gt;10% of their fasting baseline weight, if the estimated odds ratio (liraglutide 3.0 mg/liraglutide placebo) was statistically significantly greater than one.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>4.34</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>3.54</ci_lower_limit>
            <ci_upper_limit>5.32</ci_upper_limit>
            <estimate_desc>The model included treatment, country, sex, pre-diabetes status at screening, BMI stratum and an interaction between pre-diabetes status at screening and BMI stratum as fixed factors, and the baseline value as covariate.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Proportion of Subjects With Onset of Type 2 Diabetes</title>
        <description>Proportion of subjects with onset of Type 2 diabetes mellitus (T2DM) at week 160 (main + extension treatment period) among subjects with pre-diabetes at baseline - evaluated as time to onset of T2DM. Subjects included in FAS, who were stratified to 160-weeks of treatment (i.e., excluding 37 subjects with pre-diabetes who entered the re-randomised period and including 6 subjects without pre-diabetes incorrectly stratified to the 160-week treatment period).</description>
        <time_frame>At 160 weeks</time_frame>
        <population>Subjects included in the FAS, who were stratified to 160-weeks of treatment; all randomised subjects who were exposed to at least one dose of trial product (liraglutide 3.0 mg or liraglutide placebo) and with at least one post-baseline efficacy measurement, who were stratified to 160-weeks of treatment. Missing data were imputed using LOCF.</population>
        <group_list>
          <group group_id="O1">
            <title>Liraglutide 3.0 mg (160-Week)</title>
            <description>Subjects belong to Arm 3 (with pre-diabetes at screening), received liraglutide 3.0 mg, once daily (OD) subcutaneously (s.c. injection, under the skin) for 160 weeks, from randomisation.</description>
          </group>
          <group group_id="O2">
            <title>Liraglutide Placebo (160-Week)</title>
            <description>Subjects belong to Arm 4 (with pre-diabetes at screening), received liraglutide placebo, once daily (OD) subcutaneously (s.c. injection, under the skin) for 160 weeks, from randomisation.</description>
          </group>
        </group_list>
        <measure>
          <title>Proportion of Subjects With Onset of Type 2 Diabetes</title>
          <description>Proportion of subjects with onset of Type 2 diabetes mellitus (T2DM) at week 160 (main + extension treatment period) among subjects with pre-diabetes at baseline - evaluated as time to onset of T2DM. Subjects included in FAS, who were stratified to 160-weeks of treatment (i.e., excluding 37 subjects with pre-diabetes who entered the re-randomised period and including 6 subjects without pre-diabetes incorrectly stratified to the 160-week treatment period).</description>
          <population>Subjects included in the FAS, who were stratified to 160-weeks of treatment; all randomised subjects who were exposed to at least one dose of trial product (liraglutide 3.0 mg or liraglutide placebo) and with at least one post-baseline efficacy measurement, who were stratified to 160-weeks of treatment. Missing data were imputed using LOCF.</population>
          <units>Subject</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1472"/>
                <count group_id="O2" value="738"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26"/>
                    <measurement group_id="O2" value="46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>If the estimated time-to-event ratio (liraglutide 3.0 mg/ placebo), as assessed by the survival endpoint describing the time until onset of T2DM (‘diabetes-free time’), is statistically significantly &gt;1, then liraglutide 3.0 mg was to be considered superior to placebo in delaying the onset of T2DM in subjects with pre-diabetes at baseline. Weibull model was used; included treatment, sex and BMI stratification factor as fixed factors and baseline FPG as a covariate.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;.0001</p_value>
            <method>Weibull analysis</method>
            <param_type>Treatment estimate</param_type>
            <param_value>2.681</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.856</ci_lower_limit>
            <ci_upper_limit>3.872</ci_upper_limit>
            <estimate_desc>The treatment estimate was the factor that the time to event is multiplied with for liraglutide 3.0 mg compared to placebo.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Waist Circumference (cm)</title>
        <description>The observed mean change from baseline in waist circumference (cm) after 56-weeks of treatment (main treatment period).</description>
        <time_frame>Week 0, Week 56</time_frame>
        <population>The FAS included all randomised subjects who were exposed to at least one dose of trial product (liraglutide 3.0 mg or liraglutide placebo) and who provided at least one post-baseline efficacy value. Missing data were imputed using LOCF.</population>
        <group_list>
          <group group_id="O1">
            <title>Liraglutide 3.0 mg (56-Week)</title>
            <description>Subjects belong to Arm 1 (with no pre-diabetes at screening) and Arm 3 (with pre-diabetes at screening), received liraglutide 3.0 mg, once daily (OD) subcutaneously (s.c. injection, under the skin) for 56 weeks, from randomisation.</description>
          </group>
          <group group_id="O2">
            <title>Liraglutide Placebo (56-Week)</title>
            <description>Subjects belong to Arm 2 (with no pre-diabetes at screening) and Arm 4 (with pre-diabetes at screening), received liraglutide Placebo, once daily (OD) subcutaneously (s.c. injection, under the skin) for 56 weeks, from randomisation.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Waist Circumference (cm)</title>
          <description>The observed mean change from baseline in waist circumference (cm) after 56-weeks of treatment (main treatment period).</description>
          <population>The FAS included all randomised subjects who were exposed to at least one dose of trial product (liraglutide 3.0 mg or liraglutide placebo) and who provided at least one post-baseline efficacy value. Missing data were imputed using LOCF.</population>
          <units>cm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2437"/>
                <count group_id="O2" value="1225"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-8.19" spread="7.31"/>
                    <measurement group_id="O2" value="-3.94" spread="6.58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Waist Circumference (Subjects With Pre-diabetes at Baseline)</title>
        <description>The observed mean change from baseline in waist circumference (subjects with pre-diabetes at baseline) after 160 weeks of treatment (main + extension treatment period). Subjects included in FAS, who were stratified to 160-weeks of treatment (i.e., excluding 37 subjects with pre-diabetes who entered the re-randomised period and including 6 subjects without pre-diabetes incorrectly stratified to the 160-week treatment period).</description>
        <time_frame>Week 0, week 160</time_frame>
        <population>Subjects included in the FAS, who were stratified to 160-weeks of treatment; all randomised subjects who were exposed to at least one dose of trial product (liraglutide 3.0 mg or liraglutide placebo) and with at least one post-baseline efficacy measurement, who were stratified to 160-weeks of treatment. Missing data were imputed using LOCF.</population>
        <group_list>
          <group group_id="O1">
            <title>Liraglutide 3.0 mg (160-Week)</title>
            <description>Subjects belong to Arm 3 (with pre-diabetes at screening), received liraglutide 3.0 mg, once daily (OD) subcutaneously (s.c. injection, under the skin) for 160 weeks, from randomisation.</description>
          </group>
          <group group_id="O2">
            <title>Liraglutide Placebo (160-Week)</title>
            <description>Subjects belong to Arm 4 (with pre-diabetes at screening), received liraglutide placebo, once daily (OD) subcutaneously (s.c. injection, under the skin) for 160 weeks, from randomisation.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Waist Circumference (Subjects With Pre-diabetes at Baseline)</title>
          <description>The observed mean change from baseline in waist circumference (subjects with pre-diabetes at baseline) after 160 weeks of treatment (main + extension treatment period). Subjects included in FAS, who were stratified to 160-weeks of treatment (i.e., excluding 37 subjects with pre-diabetes who entered the re-randomised period and including 6 subjects without pre-diabetes incorrectly stratified to the 160-week treatment period).</description>
          <population>Subjects included in the FAS, who were stratified to 160-weeks of treatment; all randomised subjects who were exposed to at least one dose of trial product (liraglutide 3.0 mg or liraglutide placebo) and with at least one post-baseline efficacy measurement, who were stratified to 160-weeks of treatment. Missing data were imputed using LOCF.</population>
          <units>cm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1472"/>
                <count group_id="O2" value="738"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-6.87" spread="8.28"/>
                    <measurement group_id="O2" value="-3.37" spread="7.47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pre-diabetes Status After 56 Weeks of Treatment</title>
        <description>Observed percentage of subjects with pre-diabetes status after 56 weeks of treatment (main treatment period).</description>
        <time_frame>Week 0, Week 56</time_frame>
        <population>The FAS included all randomised subjects who were exposed to at least one dose of trial product (liraglutide 3.0 mg or liraglutide placebo) and who provided at least one post-baseline efficacy value. Missing data were imputed using LOCF.</population>
        <group_list>
          <group group_id="O1">
            <title>Liraglutide 3.0 mg (56-Week)</title>
            <description>Subjects belong to Arm 1 (with no pre-diabetes at screening) and Arm 3 (with pre-diabetes at screening), received liraglutide 3.0 mg, once daily (OD) subcutaneously (s.c. injection, under the skin) for 56 weeks, from randomisation.</description>
          </group>
          <group group_id="O2">
            <title>Liraglutide Placebo (56-Week)</title>
            <description>Subjects belong to Arm 2 (with no pre-diabetes at screening) and Arm 4 (with pre-diabetes at screening), received liraglutide Placebo, once daily (OD) subcutaneously (s.c. injection, under the skin) for 56 weeks, from randomisation.</description>
          </group>
        </group_list>
        <measure>
          <title>Pre-diabetes Status After 56 Weeks of Treatment</title>
          <description>Observed percentage of subjects with pre-diabetes status after 56 weeks of treatment (main treatment period).</description>
          <population>The FAS included all randomised subjects who were exposed to at least one dose of trial product (liraglutide 3.0 mg or liraglutide placebo) and who provided at least one post-baseline efficacy value. Missing data were imputed using LOCF.</population>
          <units>percentage of subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2437"/>
                <count group_id="O2" value="1225"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>With No Pre-diabetes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="78.3"/>
                    <measurement group_id="O2" value="50.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>With Pre-diabetes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.6"/>
                    <measurement group_id="O2" value="46.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>With Transient Type 2 Diabetes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.9"/>
                    <measurement group_id="O2" value="1.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>With Confirmed Type 2 Diabetes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.2"/>
                    <measurement group_id="O2" value="1.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pre-diabetes Status in Subject With Pre-diabetes at Baseline After 160 Weeks of Treatment</title>
        <description>Observed percentage of subjects (subjects with pre-diabetes at baseline) with pre-diabetes status after 160 weeks of treatment (main + extension treatment period). Subjects included in FAS, who were stratified to 160-weeks of treatment (i.e., excluding 37 subjects with pre-diabetes who entered the re-randomised period and including 6 subjects without pre-diabetes incorrectly stratified to the 160-week treatment period).</description>
        <time_frame>Week 0, week 160</time_frame>
        <population>Subjects included in the FAS, who were stratified to 160-weeks of treatment; all randomised subjects who were exposed to at least one dose of trial product (liraglutide 3.0 mg or liraglutide placebo) and with at least one post-baseline efficacy measurement, who were stratified to 160-weeks of treatment. Missing data were imputed using LOCF.</population>
        <group_list>
          <group group_id="O1">
            <title>Liraglutide 3.0 mg (160-Week)</title>
            <description>Subjects belong to Arm 3 (with pre-diabetes at screening), received liraglutide 3.0 mg, once daily (OD) subcutaneously (s.c. injection, under the skin) for 160 weeks, from randomisation.</description>
          </group>
          <group group_id="O2">
            <title>Liraglutide Placebo (160-Week)</title>
            <description>Subjects belong to Arm 4 (with pre-diabetes at screening), received liraglutide placebo, once daily (OD) subcutaneously (s.c. injection, under the skin) for 160 weeks, from randomisation.</description>
          </group>
        </group_list>
        <measure>
          <title>Pre-diabetes Status in Subject With Pre-diabetes at Baseline After 160 Weeks of Treatment</title>
          <description>Observed percentage of subjects (subjects with pre-diabetes at baseline) with pre-diabetes status after 160 weeks of treatment (main + extension treatment period). Subjects included in FAS, who were stratified to 160-weeks of treatment (i.e., excluding 37 subjects with pre-diabetes who entered the re-randomised period and including 6 subjects without pre-diabetes incorrectly stratified to the 160-week treatment period).</description>
          <population>Subjects included in the FAS, who were stratified to 160-weeks of treatment; all randomised subjects who were exposed to at least one dose of trial product (liraglutide 3.0 mg or liraglutide placebo) and with at least one post-baseline efficacy measurement, who were stratified to 160-weeks of treatment. Missing data were imputed using LOCF.</population>
          <units>percentage of subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1472"/>
                <count group_id="O2" value="738"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>With No Pre-diabetes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="65.9"/>
                    <measurement group_id="O2" value="36.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>With Pre-diabetes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31.3"/>
                    <measurement group_id="O2" value="54.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>With Transient Type 2 Diabetes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.1"/>
                    <measurement group_id="O2" value="2.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>With Confirmed Type 2 Diabetes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.8"/>
                    <measurement group_id="O2" value="6.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From Baseline in Fasting Body Weight (Subjects With Pre-diabetes at Baseline)</title>
        <description>The observed mean change from baseline in fasting body weight (subjects with pre-diabetes at baseline) after 160 weeks of treatment (main + extension treatment period). Subjects included in FAS, who were stratified to 160-weeks of treatment (i.e., excluding 37 subjects with pre-diabetes who entered the re-randomised period and including 6 subjects without pre-diabetes incorrectly stratified to the 160-week treatment period).</description>
        <time_frame>Week 0, week 160</time_frame>
        <population>Subjects included in the FAS, who were stratified to 160-weeks of treatment; all randomised subjects who were exposed to at least one dose of trial product (liraglutide 3.0 mg or liraglutide placebo) and with at least one post-baseline efficacy measurement, who were stratified to 160-weeks of treatment. Missing data were imputed using LOCF.</population>
        <group_list>
          <group group_id="O1">
            <title>Liraglutide 3.0 mg (160-Week)</title>
            <description>Subjects belong to Arm 3 (with pre-diabetes at screening), received liraglutide 3.0 mg, once daily (OD) subcutaneously (s.c. injection, under the skin) for 160 weeks, from randomisation.</description>
          </group>
          <group group_id="O2">
            <title>Liraglutide Placebo (160-Week)</title>
            <description>Subjects belong to Arm 4 (with pre-diabetes at screening), received liraglutide placebo, once daily (OD) subcutaneously (s.c. injection, under the skin) for 160 weeks, from randomisation.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline in Fasting Body Weight (Subjects With Pre-diabetes at Baseline)</title>
          <description>The observed mean change from baseline in fasting body weight (subjects with pre-diabetes at baseline) after 160 weeks of treatment (main + extension treatment period). Subjects included in FAS, who were stratified to 160-weeks of treatment (i.e., excluding 37 subjects with pre-diabetes who entered the re-randomised period and including 6 subjects without pre-diabetes incorrectly stratified to the 160-week treatment period).</description>
          <population>Subjects included in the FAS, who were stratified to 160-weeks of treatment; all randomised subjects who were exposed to at least one dose of trial product (liraglutide 3.0 mg or liraglutide placebo) and with at least one post-baseline efficacy measurement, who were stratified to 160-weeks of treatment. Missing data were imputed using LOCF.</population>
          <units>percent change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1467"/>
                <count group_id="O2" value="734"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-6.14" spread="7.34"/>
                    <measurement group_id="O2" value="-1.89" spread="6.27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Proportion of Subjects Losing at Least 5% and Proportion of Subjects Losing More Than 10% of Baseline Fasting Body Weight (Subjects With Pre-diabetes at Baseline)</title>
        <description>Percentage of subjects losing &gt;=5% and percentage of subjects losing &gt;10% of baseline fasting body weight (pre-diabetic subjects at baseline) after 160-weeks of treatment (main + extension treatment period). Subjects included in FAS, who were stratified to 160-weeks of treatment (i.e., excluding 37 subjects with pre-diabetes who entered the re-randomised period and including 6 subjects without pre-diabetes incorrectly stratified to the 160-week treatment period).</description>
        <time_frame>At 160 weeks</time_frame>
        <population>Subjects included in the FAS, who were stratified to 160-weeks of treatment; all randomised subjects who were exposed to at least one dose of trial product (liraglutide 3.0 mg or liraglutide placebo) and with at least one post-baseline efficacy measurement, who were stratified to 160-weeks of treatment. Missing data were imputed using LOCF.</population>
        <group_list>
          <group group_id="O1">
            <title>Liraglutide 3.0 mg (160-Week)</title>
            <description>Subjects belong to Arm 3 (with pre-diabetes at screening), received liraglutide 3.0 mg, once daily (OD) subcutaneously (s.c. injection, under the skin) for 160 weeks, from randomisation.</description>
          </group>
          <group group_id="O2">
            <title>Liraglutide Placebo (160-Week)</title>
            <description>Subjects belong to Arm 4 (with pre-diabetes at screening), received liraglutide placebo, once daily (OD) subcutaneously (s.c. injection, under the skin) for 160 weeks, from randomisation.</description>
          </group>
        </group_list>
        <measure>
          <title>Proportion of Subjects Losing at Least 5% and Proportion of Subjects Losing More Than 10% of Baseline Fasting Body Weight (Subjects With Pre-diabetes at Baseline)</title>
          <description>Percentage of subjects losing &gt;=5% and percentage of subjects losing &gt;10% of baseline fasting body weight (pre-diabetic subjects at baseline) after 160-weeks of treatment (main + extension treatment period). Subjects included in FAS, who were stratified to 160-weeks of treatment (i.e., excluding 37 subjects with pre-diabetes who entered the re-randomised period and including 6 subjects without pre-diabetes incorrectly stratified to the 160-week treatment period).</description>
          <population>Subjects included in the FAS, who were stratified to 160-weeks of treatment; all randomised subjects who were exposed to at least one dose of trial product (liraglutide 3.0 mg or liraglutide placebo) and with at least one post-baseline efficacy measurement, who were stratified to 160-weeks of treatment. Missing data were imputed using LOCF.</population>
          <units>percentage of subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1467"/>
                <count group_id="O2" value="734"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Losing &gt;=5% of baseline body weight</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="49.6"/>
                    <measurement group_id="O2" value="23.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Losing &gt;10% of baseline body weight</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24.8"/>
                    <measurement group_id="O2" value="9.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Week 56 in Fasting Body Weight (%) (Re-randomised Subjects With No Pre-diabetes)</title>
        <description>The observed mean change in fasting body weight (%) from week 56 to week 68 in re-randomised subjects (with no pre-diabetes at baseline) after 12-weeks of treatment (re-randomised treatment period).</description>
        <time_frame>Week 56, Week 68</time_frame>
        <population>The FAS included all randomised subjects who were exposed to at least one dose of trial product (liraglutide 3.0 mg or liraglutide placebo) and who provided at least one post-baseline efficacy value. Missing data were imputed using LOCF.</population>
        <group_list>
          <group group_id="O1">
            <title>Liraglutide 3.0mg (week0-56)/Liraglutide 3.0mg (week56-68)</title>
            <description>Arm 1A: Subjects of Arm 1 (with no pre-diabetes at screening) receiving liraglutide 3.0 mg, once daily (OD) subcutaneously (s.c. injection, under the skin) for 56 weeks were re-randomised (1:1 into liraglutide 3.0 mg or liraglutide placebo) to continue treatment with liraglutide 3.0 mg for the next 12 weeks (weeks 56-68), followed by a 2 weeks off-drug follow-up period.</description>
          </group>
          <group group_id="O2">
            <title>Liraglutide 3.0mg (week0-56)/Liraglutide Placebo (week56-68)</title>
            <description>Arm 1B: Subjects of Arm 1 (with no pre-diabetes at screening) receiving liraglutide 3.0 mg, once daily (OD) subcutaneously (s.c. injection, under the skin) for 56 weeks were re-randomised (1:1 into liraglutide 3.0 mg or liraglutide placebo) to receive liraglutide placebo for the next 12 weeks (weeks 56-68), followed by a 2 weeks off-drug follow-up period.</description>
          </group>
          <group group_id="O3">
            <title>Liraglutide Placebo, no Pre-diabetes</title>
            <description>Arm 2: Subjects with no pre-diabetes at screening received liraglutide placebo once daily (OD) subcutaneously (s.c. injection, under the skin) for 56 weeks and then continued with liraglutide placebo for additional 12 weeks (weeks 56-68), followed by a 2 weeks off-drug follow-up period. The total duration of this treatment arm from randomisation to follow-up was 70 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Week 56 in Fasting Body Weight (%) (Re-randomised Subjects With No Pre-diabetes)</title>
          <description>The observed mean change in fasting body weight (%) from week 56 to week 68 in re-randomised subjects (with no pre-diabetes at baseline) after 12-weeks of treatment (re-randomised treatment period).</description>
          <population>The FAS included all randomised subjects who were exposed to at least one dose of trial product (liraglutide 3.0 mg or liraglutide placebo) and who provided at least one post-baseline efficacy value. Missing data were imputed using LOCF.</population>
          <units>percent change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="349"/>
                <count group_id="O2" value="346"/>
                <count group_id="O3" value="299"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.69" spread="2.58"/>
                    <measurement group_id="O2" value="2.91" spread="3.01"/>
                    <measurement group_id="O3" value="0.28" spread="2.39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Fasting Body Weight (%) (Re-randomised Subjects With No Pre-diabetes)</title>
        <description>The observed mean change from baseline in fasting body weight (%) in re-randomised subjects (with no pre-diabetes at baseline) after 68 weeks of treatment (main + re-randomised treatment period).</description>
        <time_frame>Week 0, Week 68</time_frame>
        <population>The FAS included all randomised subjects who were exposed to at least one dose of trial product (liraglutide 3.0 mg or liraglutide placebo) and who provided at least one post-baseline efficacy value. Missing data were imputed using LOCF.</population>
        <group_list>
          <group group_id="O1">
            <title>Liraglutide 3.0mg (week0-56)/Liraglutide 3.0mg (week56-68)</title>
            <description>Arm 1A: Subjects of Arm 1 (with no pre-diabetes at screening) receiving liraglutide 3.0 mg, once daily (OD) subcutaneously (s.c. injection, under the skin) for 56 weeks were re-randomised (1:1 into liraglutide 3.0 mg or liraglutide placebo) to continue treatment with liraglutide 3.0 mg for the next 12 weeks (weeks 56-68), followed by a 2 weeks off-drug follow-up period.</description>
          </group>
          <group group_id="O2">
            <title>Liraglutide 3.0mg (week0-56)/Liraglutide Placebo (week56-68)</title>
            <description>Arm 1B: Subjects of Arm 1 (with no pre-diabetes at screening) receiving liraglutide 3.0 mg, once daily (OD) subcutaneously (s.c. injection, under the skin) for 56 weeks were re-randomised (1:1 into liraglutide 3.0 mg or liraglutide placebo) to receive liraglutide placebo for the next 12 weeks (weeks 56-68), followed by a 2 weeks off-drug follow-up period.</description>
          </group>
          <group group_id="O3">
            <title>Liraglutide Placebo, no Pre-diabetes</title>
            <description>Arm 2: Subjects with no pre-diabetes at screening received liraglutide placebo once daily (OD) subcutaneously (s.c. injection, under the skin) for 56 weeks and then continued with liraglutide placebo for additional 12 weeks (weeks 56-68), followed by a 2 weeks off-drug follow-up period. The total duration of this treatment arm from randomisation to follow-up was 70 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Fasting Body Weight (%) (Re-randomised Subjects With No Pre-diabetes)</title>
          <description>The observed mean change from baseline in fasting body weight (%) in re-randomised subjects (with no pre-diabetes at baseline) after 68 weeks of treatment (main + re-randomised treatment period).</description>
          <population>The FAS included all randomised subjects who were exposed to at least one dose of trial product (liraglutide 3.0 mg or liraglutide placebo) and who provided at least one post-baseline efficacy value. Missing data were imputed using LOCF.</population>
          <units>percent change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="349"/>
                <count group_id="O2" value="347"/>
                <count group_id="O3" value="298"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-8.44" spread="7.23"/>
                    <measurement group_id="O2" value="-6.77" spread="7.67"/>
                    <measurement group_id="O3" value="-3.11" spread="7.52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>For Arm 1 and Arm 2: week 0 to week 70 (68 weeks of treatment period + 2 weeks of follow-up). For Arm 3 and Arm 4: week 0 to week 172 (160 weeks of treatment period + 12 weeks of follow-up).</time_frame>
      <desc>A total of 37 pre-diabetic subjects erroneously entered the re randomised period and their adverse events (AEs) were counted under the “pre-diabetic arms” (Arm 3 and Arm 4). A total of 6 subjects without pre-diabetes incorrectly stratified to the 160-week treatment period and their AEs were counted under the “no pre-diabetes arms” (Arm 1 and Arm 2)</desc>
      <group_list>
        <group group_id="E1">
          <title>Liraglutide 3.0 mg, Pre-diabetes</title>
          <description>Arm 3: Subjects with pre-diabetes at screening received liraglutide 3.0 mg, once daily (OD) subcutaneously (s.c. injection, under the skin) for initial 56 weeks then continued treatment till 160 weeks, followed by an off-drug, observational follow-up period of 12 weeks. The total duration of this treatment arm from randomisation to follow-up was 172 weeks.</description>
        </group>
        <group group_id="E2">
          <title>Liraglutide Placebo, Pre-diabetes</title>
          <description>Arm 4: Subjects with pre-diabetes at screening received liraglutide placebo once daily (OD) subcutaneously (s.c. injection, under the skin) for initial 56 weeks then continued treatment till 160 weeks, followed by an off-drug, observational follow-up period of 12 weeks. The total duration of this treatment arm from randomisation to follow-up was 172 weeks.</description>
        </group>
        <group group_id="E3">
          <title>Liraglutide 3.0 mg, no Pre-diabetes</title>
          <description>Arm 1 (Arm 1A + Arm 1B): Subjects with no pre-diabetes at screening received liraglutide 3.0 mg, once daily (OD) subcutaneously (s.c. injection, under the skin) for 56 weeks followed by a re-randomisation (1:1 into liraglutide 3.0 mg or liraglutide placebo) period of 12 weeks (weeks 56-68) and then an off-drug follow-up period of 2 weeks. The total duration of this treatment arm from randomisation to follow-up was 70 weeks.</description>
        </group>
        <group group_id="E4">
          <title>Liraglutide Placebo, no Pre-diabetes</title>
          <description>Arm 2: Subjects with no pre-diabetes at screening received liraglutide placebo once daily (OD) subcutaneously (s.c. injection, under the skin) for 56 weeks and then continued with liraglutide placebo for additional 12 weeks (weeks 56-68), followed by a 2 weeks off-drug follow-up period. The total duration of this treatment arm from randomisation to follow-up was 70 weeks.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA version 15.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="230" subjects_at_risk="1524"/>
                <counts group_id="E2" subjects_affected="96" subjects_at_risk="755"/>
                <counts group_id="E3" subjects_affected="59" subjects_at_risk="957"/>
                <counts group_id="E4" subjects_affected="19" subjects_at_risk="487"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1524"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="755"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="957"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="487"/>
              </event>
              <event>
                <sub_title>Bandaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1524"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="755"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="957"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="487"/>
              </event>
              <event>
                <sub_title>Hypercoagulation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1524"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="755"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="957"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="487"/>
              </event>
              <event>
                <sub_title>Leukocytosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1524"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="755"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="957"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="487"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Acute coronary syndrome</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1524"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="755"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="957"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="487"/>
              </event>
              <event>
                <sub_title>Angina unstable</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1524"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="755"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="957"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="487"/>
              </event>
              <event>
                <sub_title>Aortic valve disease mixed</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1524"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="755"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="957"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="487"/>
              </event>
              <event>
                <sub_title>Aortic valve stenosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1524"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="755"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="957"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="487"/>
              </event>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="1524"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="755"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="957"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="487"/>
              </event>
              <event>
                <sub_title>Atrial flutter</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1524"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="755"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="957"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="487"/>
              </event>
              <event>
                <sub_title>Cardiac failure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1524"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="755"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="957"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="487"/>
              </event>
              <event>
                <sub_title>Cardiac failure chronic</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1524"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="755"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="957"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="487"/>
              </event>
              <event>
                <sub_title>Cardiac tamponade</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1524"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="755"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="957"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="487"/>
              </event>
              <event>
                <sub_title>Cardio-respiratory arrest</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1524"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="755"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="957"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="487"/>
              </event>
              <event>
                <sub_title>Cardiomegaly</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1524"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="755"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="957"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="487"/>
              </event>
              <event>
                <sub_title>Congestive cardiomyopathy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1524"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="755"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="957"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="487"/>
              </event>
              <event>
                <sub_title>Coronary artery disease</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1524"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="755"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="957"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="487"/>
              </event>
              <event>
                <sub_title>Coronary artery stenosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1524"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="755"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="957"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="487"/>
              </event>
              <event>
                <sub_title>Hypertensive heart disease</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1524"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="755"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="957"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="487"/>
              </event>
              <event>
                <sub_title>Left ventricular dysfunction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1524"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="755"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="957"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="487"/>
              </event>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1524"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="755"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="957"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="487"/>
              </event>
              <event>
                <sub_title>Myocardial ischaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1524"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="755"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="957"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="487"/>
              </event>
              <event>
                <sub_title>Palpitations</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1524"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="755"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="957"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="487"/>
              </event>
              <event>
                <sub_title>Pericarditis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1524"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="755"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="957"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="487"/>
              </event>
              <event>
                <sub_title>Supraventricular tachycardia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1524"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="755"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="957"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="487"/>
              </event>
              <event>
                <sub_title>Tachycardia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1524"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="755"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="957"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="487"/>
              </event>
              <event>
                <sub_title>Ventricular fibrillation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1524"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="755"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="957"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="487"/>
              </event>
              <event>
                <sub_title>Ventricular tachycardia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1524"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="755"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="957"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="487"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Congenital, familial and genetic disorders</title>
            <event_list>
              <event>
                <sub_title>Dermoid cyst</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1524"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="755"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="957"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="487"/>
              </event>
              <event>
                <sub_title>Multiple endocrine adenomatosis Type I</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1524"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="755"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="957"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="487"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Vertigo</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1524"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="755"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="957"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="487"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Basedow</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1524"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="755"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="957"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="487"/>
              </event>
              <event>
                <sub_title>Goitre</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1524"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="755"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="957"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="487"/>
              </event>
              <event>
                <sub_title>Hyperparathyroidism primary</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1524"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="755"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="957"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="487"/>
              </event>
              <event>
                <sub_title>Hyperthyroidism</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1524"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="755"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="957"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="487"/>
              </event>
              <event>
                <sub_title>Toxic nodular goitre</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1524"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="755"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="957"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="487"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Cataract</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1524"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="755"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="957"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="487"/>
              </event>
              <event>
                <sub_title>Retinal detachment</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1524"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="755"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="957"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="487"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal hernia</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="1524"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="755"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="957"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="487"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="1524"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="755"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="957"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="487"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1524"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="755"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="957"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="487"/>
              </event>
              <event>
                <sub_title>Anal fissure</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1524"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="755"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="957"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="487"/>
              </event>
              <event>
                <sub_title>Anal fistula</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1524"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="755"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="957"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="487"/>
              </event>
              <event>
                <sub_title>Barrett</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1524"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="755"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="957"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="487"/>
              </event>
              <event>
                <sub_title>Caecitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1524"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="755"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="957"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="487"/>
              </event>
              <event>
                <sub_title>Colitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1524"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="755"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="957"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="487"/>
              </event>
              <event>
                <sub_title>Colitis ischaemic</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1524"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="755"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="957"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="487"/>
              </event>
              <event>
                <sub_title>Colitis ulcerative</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1524"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="755"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="957"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="487"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1524"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="755"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="957"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="487"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1524"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="755"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="957"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="487"/>
              </event>
              <event>
                <sub_title>Diverticulum</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1524"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="755"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="957"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="487"/>
              </event>
              <event>
                <sub_title>Faecal incontinence</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1524"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="755"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="957"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="487"/>
              </event>
              <event>
                <sub_title>Gastric ulcer haemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1524"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="755"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="957"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="487"/>
              </event>
              <event>
                <sub_title>Gastritis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1524"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="755"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="957"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="487"/>
              </event>
              <event>
                <sub_title>Gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1524"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="755"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="957"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="487"/>
              </event>
              <event>
                <sub_title>Gastrooesophageal reflux disease</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1524"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="755"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="957"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="487"/>
              </event>
              <event>
                <sub_title>Haemorrhoids</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1524"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="755"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="957"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="487"/>
              </event>
              <event>
                <sub_title>Hiatus hernia</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="1524"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="755"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="957"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="487"/>
              </event>
              <event>
                <sub_title>Inguinal hernia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1524"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="755"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="957"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="487"/>
              </event>
              <event>
                <sub_title>Intestinal obstruction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1524"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="755"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="957"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="487"/>
              </event>
              <event>
                <sub_title>Intestinal perforation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1524"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="755"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="957"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="487"/>
              </event>
              <event>
                <sub_title>Intestinal prolapse</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1524"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="755"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="957"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="487"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1524"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="755"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="957"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="487"/>
              </event>
              <event>
                <sub_title>Pancreatic cyst</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1524"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="755"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="957"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="487"/>
              </event>
              <event>
                <sub_title>Pancreatitis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1524"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="755"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="957"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="487"/>
              </event>
              <event>
                <sub_title>Pancreatitis acute</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="1524"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="755"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="957"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="487"/>
              </event>
              <event>
                <sub_title>Rectal haemorrhage</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="1524"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="755"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="957"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="487"/>
              </event>
              <event>
                <sub_title>Umbilical hernia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1524"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="755"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="957"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="487"/>
              </event>
              <event>
                <sub_title>Umbilical hernia, obstructive</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1524"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="755"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="957"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="487"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1524"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="755"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="957"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="487"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chest discomfort</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1524"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="755"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="957"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="487"/>
              </event>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1524"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="755"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="957"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="487"/>
              </event>
              <event>
                <sub_title>Cyst</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1524"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="755"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="957"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="487"/>
              </event>
              <event>
                <sub_title>Device dislocation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1524"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="755"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="957"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="487"/>
              </event>
              <event>
                <sub_title>Inflammation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1524"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="755"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="957"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="487"/>
              </event>
              <event>
                <sub_title>Medical device complication</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1524"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="755"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="957"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="487"/>
              </event>
              <event>
                <sub_title>Metaplasia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1524"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="755"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="957"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="487"/>
              </event>
              <event>
                <sub_title>Non-cardiac chest pain</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="1524"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="755"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="957"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="487"/>
              </event>
              <event>
                <sub_title>Ulcer haemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1524"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="755"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="957"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="487"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Bile duct stone</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="1524"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="755"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="957"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="487"/>
              </event>
              <event>
                <sub_title>Biliary colic</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1524"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="755"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="957"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="487"/>
              </event>
              <event>
                <sub_title>Cholecystitis</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="1524"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="755"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="957"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="487"/>
              </event>
              <event>
                <sub_title>Cholecystitis acute</sub_title>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="1524"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="755"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="957"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="487"/>
              </event>
              <event>
                <sub_title>Cholecystitis chronic</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1524"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="755"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="957"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="487"/>
              </event>
              <event>
                <sub_title>Cholelithiasis</sub_title>
                <counts group_id="E1" events="23" subjects_affected="22" subjects_at_risk="1524"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="755"/>
                <counts group_id="E3" events="7" subjects_affected="7" subjects_at_risk="957"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="487"/>
              </event>
              <event>
                <sub_title>Gallbladder polyp</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1524"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="755"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="957"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="487"/>
              </event>
              <event>
                <sub_title>Hepatic cyst</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1524"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="755"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="957"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="487"/>
              </event>
              <event>
                <sub_title>Hepatic lesion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1524"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="755"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="957"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="487"/>
              </event>
              <event>
                <sub_title>Hepatitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1524"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="755"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="957"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="487"/>
              </event>
              <event>
                <sub_title>Hepatitis acute</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1524"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="755"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="957"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="487"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Amyloidosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1524"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="755"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="957"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="487"/>
              </event>
              <event>
                <sub_title>Anaphylactic reaction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1524"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="755"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="957"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="487"/>
              </event>
              <event>
                <sub_title>Drug hypersensitivity</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1524"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="755"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="957"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="487"/>
              </event>
              <event>
                <sub_title>Hypersensitivity</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1524"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="755"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="957"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="487"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Abdominal wall infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1524"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="755"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="957"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="487"/>
              </event>
              <event>
                <sub_title>Abscess neck</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1524"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="755"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="957"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="487"/>
              </event>
              <event>
                <sub_title>Alveolar osteitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1524"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="755"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="957"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="487"/>
              </event>
              <event>
                <sub_title>Anal abscess</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1524"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="755"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="957"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="487"/>
              </event>
              <event>
                <sub_title>Appendicitis</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="1524"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="755"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="957"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="487"/>
              </event>
              <event>
                <sub_title>Arthritis bacterial</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1524"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="755"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="957"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="487"/>
              </event>
              <event>
                <sub_title>Arthritis infective</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1524"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="755"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="957"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="487"/>
              </event>
              <event>
                <sub_title>Brain abscess</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1524"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="755"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="957"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="487"/>
              </event>
              <event>
                <sub_title>Breast abscess</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1524"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="755"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="957"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="487"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1524"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="755"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="957"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="487"/>
              </event>
              <event>
                <sub_title>Bronchopneumonia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1524"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="755"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="957"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="487"/>
              </event>
              <event>
                <sub_title>Campylobacter gastroenteritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1524"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="755"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="957"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="487"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="1524"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="755"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="957"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="487"/>
              </event>
              <event>
                <sub_title>Clostridium difficile colitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1524"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="755"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="957"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="487"/>
              </event>
              <event>
                <sub_title>Cytomegalovirus infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1524"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="755"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="957"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="487"/>
              </event>
              <event>
                <sub_title>Diverticulitis</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="1524"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="755"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="957"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="487"/>
              </event>
              <event>
                <sub_title>Empyema</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1524"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="755"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="957"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="487"/>
              </event>
              <event>
                <sub_title>Erysipelas</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="1524"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="755"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="957"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="487"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="1524"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="755"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="957"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="487"/>
              </event>
              <event>
                <sub_title>Gastroenteritis viral</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1524"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="755"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="957"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="487"/>
              </event>
              <event>
                <sub_title>Hepatitis A</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1524"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="755"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="957"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="487"/>
              </event>
              <event>
                <sub_title>Incision site infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1524"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="755"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="957"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="487"/>
              </event>
              <event>
                <sub_title>Lobar pneumonia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1524"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="755"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="957"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="487"/>
              </event>
              <event>
                <sub_title>Localised infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1524"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="755"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="957"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="487"/>
              </event>
              <event>
                <sub_title>Meningitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1524"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="755"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="957"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="487"/>
              </event>
              <event>
                <sub_title>Oophoritis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1524"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="755"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="957"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="487"/>
              </event>
              <event>
                <sub_title>Osteomyelitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1524"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="755"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="957"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="487"/>
              </event>
              <event>
                <sub_title>Pharyngotonsillitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1524"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="755"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="957"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="487"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1524"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="755"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="957"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="487"/>
              </event>
              <event>
                <sub_title>Post procedural infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1524"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="755"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="957"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="487"/>
              </event>
              <event>
                <sub_title>Postoperative wound infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1524"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="755"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="957"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="487"/>
              </event>
              <event>
                <sub_title>Pyelonephritis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1524"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="755"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="957"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="487"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1524"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="755"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="957"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="487"/>
              </event>
              <event>
                <sub_title>Septic shock</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1524"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="755"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="957"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="487"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="1524"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="755"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="957"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="487"/>
              </event>
              <event>
                <sub_title>Urosepsis</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="1524"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="755"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="957"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="487"/>
              </event>
              <event>
                <sub_title>Vulval abscess</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1524"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="755"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="957"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="487"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Accident</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1524"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="755"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="957"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="487"/>
              </event>
              <event>
                <sub_title>Animal bite</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1524"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="755"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="957"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="487"/>
              </event>
              <event>
                <sub_title>Ankle fracture</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1524"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="755"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="957"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="487"/>
              </event>
              <event>
                <sub_title>Cartilage injury</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1524"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="755"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="957"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="487"/>
              </event>
              <event>
                <sub_title>Clavicle fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1524"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="755"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="957"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="487"/>
              </event>
              <event>
                <sub_title>Drug dispensing error</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1524"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="755"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="957"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="487"/>
              </event>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1524"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="755"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="957"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="487"/>
              </event>
              <event>
                <sub_title>Fibula fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1524"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="755"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="957"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="487"/>
              </event>
              <event>
                <sub_title>Hand fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1524"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="755"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="957"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="487"/>
              </event>
              <event>
                <sub_title>Humerus fracture</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1524"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="755"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="957"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="487"/>
              </event>
              <event>
                <sub_title>Incisional hernia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1524"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="755"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="957"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="487"/>
              </event>
              <event>
                <sub_title>Joint dislocation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1524"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="755"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="957"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="487"/>
              </event>
              <event>
                <sub_title>Limb injury</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1524"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="755"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="957"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="487"/>
              </event>
              <event>
                <sub_title>Limb traumatic amputation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1524"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="755"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="957"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="487"/>
              </event>
              <event>
                <sub_title>Meniscus lesion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1524"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="755"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="957"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="487"/>
              </event>
              <event>
                <sub_title>Muscle injury</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1524"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="755"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="957"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="487"/>
              </event>
              <event>
                <sub_title>Muscle strain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1524"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="755"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="957"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="487"/>
              </event>
              <event>
                <sub_title>Post laminectomy syndrome</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1524"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="755"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="957"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="487"/>
              </event>
              <event>
                <sub_title>Post procedural complication</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1524"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="755"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="957"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="487"/>
              </event>
              <event>
                <sub_title>Post procedural haemorrhage</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1524"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="755"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="957"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="487"/>
              </event>
              <event>
                <sub_title>Procedural pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1524"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="755"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="957"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="487"/>
              </event>
              <event>
                <sub_title>Rib fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1524"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="755"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="957"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="487"/>
              </event>
              <event>
                <sub_title>Road traffic accident</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1524"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="755"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="957"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="487"/>
              </event>
              <event>
                <sub_title>Stab wound</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1524"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="755"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="957"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="487"/>
              </event>
              <event>
                <sub_title>Tendon injury</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1524"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="755"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="957"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="487"/>
              </event>
              <event>
                <sub_title>Tendon rupture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1524"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="755"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="957"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="487"/>
              </event>
              <event>
                <sub_title>Tibia fracture</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1524"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="755"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="957"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="487"/>
              </event>
              <event>
                <sub_title>Upper limb fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1524"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="755"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="957"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="487"/>
              </event>
              <event>
                <sub_title>Ureteric injury</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1524"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="755"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="957"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="487"/>
              </event>
              <event>
                <sub_title>Wound</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1524"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="755"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="957"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="487"/>
              </event>
              <event>
                <sub_title>Wrong drug administered</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1524"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="755"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="957"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="487"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1524"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="755"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="957"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="487"/>
              </event>
              <event>
                <sub_title>Amylase increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1524"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="755"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="957"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="487"/>
              </event>
              <event>
                <sub_title>Blood creatine phosphokinase increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1524"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="755"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="957"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="487"/>
              </event>
              <event>
                <sub_title>Catheterisation cardiac</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1524"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="755"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="957"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="487"/>
              </event>
              <event>
                <sub_title>Lipase increased</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1524"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="755"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="957"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="487"/>
              </event>
              <event>
                <sub_title>Weight decreased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1524"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="755"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="957"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="487"/>
              </event>
              <event>
                <sub_title>Weight increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1524"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="755"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="957"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="487"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Central obesity</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1524"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="755"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="957"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="487"/>
              </event>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1524"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="755"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="957"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="487"/>
              </event>
              <event>
                <sub_title>Hypocalcaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1524"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="755"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="957"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="487"/>
              </event>
              <event>
                <sub_title>Hypovolaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1524"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="755"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="957"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="487"/>
              </event>
              <event>
                <sub_title>Obesity</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1524"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="755"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="957"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="487"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1524"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="755"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="957"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="487"/>
              </event>
              <event>
                <sub_title>Arthritis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1524"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="755"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="957"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="487"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="1524"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="755"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="957"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="487"/>
              </event>
              <event>
                <sub_title>Bursitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1524"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="755"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="957"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="487"/>
              </event>
              <event>
                <sub_title>Cervical spinal stenosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1524"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="755"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="957"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="487"/>
              </event>
              <event>
                <sub_title>Chondromalacia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1524"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="755"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="957"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="487"/>
              </event>
              <event>
                <sub_title>Chondropathy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1524"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="755"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="957"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="487"/>
              </event>
              <event>
                <sub_title>Dupuytren</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1524"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="755"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="957"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="487"/>
              </event>
              <event>
                <sub_title>Intervertebral disc disorder</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1524"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="755"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="957"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="487"/>
              </event>
              <event>
                <sub_title>Intervertebral disc protrusion</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="1524"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="755"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="957"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="487"/>
              </event>
              <event>
                <sub_title>Joint laxity</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1524"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="755"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="957"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="487"/>
              </event>
              <event>
                <sub_title>Lumbar spinal stenosis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1524"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="755"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="957"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="487"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1524"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="755"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="957"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="487"/>
              </event>
              <event>
                <sub_title>Neck pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1524"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="755"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="957"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="487"/>
              </event>
              <event>
                <sub_title>Osteoarthritis</sub_title>
                <counts group_id="E1" events="14" subjects_affected="12" subjects_at_risk="1524"/>
                <counts group_id="E2" events="6" subjects_affected="5" subjects_at_risk="755"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="957"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="487"/>
              </event>
              <event>
                <sub_title>Osteonecrosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1524"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="755"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="957"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="487"/>
              </event>
              <event>
                <sub_title>Pain in jaw</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1524"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="755"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="957"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="487"/>
              </event>
              <event>
                <sub_title>Rheumatoid arthritis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1524"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="755"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="957"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="487"/>
              </event>
              <event>
                <sub_title>Spinal osteoarthritis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1524"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="755"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="957"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="487"/>
              </event>
              <event>
                <sub_title>Synovial cyst</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1524"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="755"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="957"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="487"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Adrenal adenoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1524"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="755"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="957"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="487"/>
              </event>
              <event>
                <sub_title>Benign salivary gland neoplasm</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1524"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="755"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="957"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="487"/>
              </event>
              <event>
                <sub_title>Bile duct cancer</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1524"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="755"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="957"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="487"/>
              </event>
              <event>
                <sub_title>Breast cancer</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="1524"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="755"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="957"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="487"/>
              </event>
              <event>
                <sub_title>Breast cancer in situ</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1524"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="755"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="957"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="487"/>
              </event>
              <event>
                <sub_title>Breast cancer metastatic</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1524"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="755"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="957"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="487"/>
              </event>
              <event>
                <sub_title>Breast cancer stage III</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1524"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="755"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="957"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="487"/>
              </event>
              <event>
                <sub_title>Carcinoid tumour of the small bowel</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1524"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="755"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="957"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="487"/>
              </event>
              <event>
                <sub_title>Cholesteatoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1524"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="755"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="957"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="487"/>
              </event>
              <event>
                <sub_title>Chronic myeloid leukaemia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1524"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="755"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="957"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="487"/>
              </event>
              <event>
                <sub_title>Colon adenoma</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1524"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="755"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="957"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="487"/>
              </event>
              <event>
                <sub_title>Colon cancer</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1524"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="755"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="957"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="487"/>
              </event>
              <event>
                <sub_title>Colon cancer metastatic</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1524"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="755"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="957"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="487"/>
              </event>
              <event>
                <sub_title>Colon cancer stage 0</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1524"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="755"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="957"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="487"/>
              </event>
              <event>
                <sub_title>Diffuse large B-cell lymphoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1524"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="755"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="957"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="487"/>
              </event>
              <event>
                <sub_title>Dysplastic naevus</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1524"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="755"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="957"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="487"/>
              </event>
              <event>
                <sub_title>Fibroadenoma of breast</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1524"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="755"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="957"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="487"/>
              </event>
              <event>
                <sub_title>Haemangioma of bone</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1524"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="755"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="957"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="487"/>
              </event>
              <event>
                <sub_title>Hepatic adenoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1524"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="755"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="957"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="487"/>
              </event>
              <event>
                <sub_title>Laryngeal cancer</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1524"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="755"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="957"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="487"/>
              </event>
              <event>
                <sub_title>Lentigo maligna</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1524"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="755"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="957"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="487"/>
              </event>
              <event>
                <sub_title>Lipoma</sub_title>
                <counts group_id="E1" events="4" subjects_affected="1" subjects_at_risk="1524"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="755"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="957"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="487"/>
              </event>
              <event>
                <sub_title>Lymphoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1524"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="755"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="957"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="487"/>
              </event>
              <event>
                <sub_title>Mantle cell lymphoma stage I</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1524"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="755"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="957"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="487"/>
              </event>
              <event>
                <sub_title>Melanocytic naevus</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1524"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="755"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="957"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="487"/>
              </event>
              <event>
                <sub_title>Neoplasm skin</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1524"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="755"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="957"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="487"/>
              </event>
              <event>
                <sub_title>Pancreatic carcinoma metastatic</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1524"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="755"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="957"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="487"/>
              </event>
              <event>
                <sub_title>Prostate cancer</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1524"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="755"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="957"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="487"/>
              </event>
              <event>
                <sub_title>Rectal cancer</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1524"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="755"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="957"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="487"/>
              </event>
              <event>
                <sub_title>Seborrhoeic keratosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1524"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="755"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="957"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="487"/>
              </event>
              <event>
                <sub_title>Thyroid cancer</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1524"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="755"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="957"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="487"/>
              </event>
              <event>
                <sub_title>Uterine leiomyoma</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="1524"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="755"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="957"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="487"/>
              </event>
              <event>
                <sub_title>Vaginal cancer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1524"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="755"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="957"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="487"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Brain stem infarction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1524"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="755"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="957"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="487"/>
              </event>
              <event>
                <sub_title>Carotid artery aneurysm</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1524"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="755"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="957"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="487"/>
              </event>
              <event>
                <sub_title>Cerebrovascular accident</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1524"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="755"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="957"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="487"/>
              </event>
              <event>
                <sub_title>Cervicobrachial syndrome</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1524"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="755"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="957"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="487"/>
              </event>
              <event>
                <sub_title>Convulsion</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="1524"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="755"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="957"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="487"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1524"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="755"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="957"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="487"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1524"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="755"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="957"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="487"/>
              </event>
              <event>
                <sub_title>Hypoaesthesia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1524"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="755"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="957"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="487"/>
              </event>
              <event>
                <sub_title>Intercostal neuralgia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1524"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="755"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="957"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="487"/>
              </event>
              <event>
                <sub_title>Intracranial pressure increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1524"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="755"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="957"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="487"/>
              </event>
              <event>
                <sub_title>Ischaemic stroke</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1524"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="755"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="957"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="487"/>
              </event>
              <event>
                <sub_title>Migraine</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1524"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="755"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="957"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="487"/>
              </event>
              <event>
                <sub_title>Presyncope</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1524"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="755"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="957"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="487"/>
              </event>
              <event>
                <sub_title>Spinal cord herniation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1524"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="755"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="957"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="487"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="1524"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="755"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="957"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="487"/>
              </event>
              <event>
                <sub_title>Transient ischaemic attack</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1524"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="755"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="957"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="487"/>
              </event>
              <event>
                <sub_title>VIIth nerve paralysis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1524"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="755"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="957"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="487"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Pregnancy, puerperium and perinatal conditions</title>
            <event_list>
              <event>
                <sub_title>Abortion missed</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1524"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="755"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="957"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="487"/>
              </event>
              <event>
                <sub_title>Abortion spontaneous</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1524"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="755"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="957"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="487"/>
              </event>
              <event>
                <sub_title>Abortion threatened</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1524"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="755"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="957"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="487"/>
              </event>
              <event>
                <sub_title>Ectopic pregnancy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1524"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="755"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="957"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="487"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1524"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="755"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="957"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="487"/>
              </event>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1524"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="755"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="957"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="487"/>
              </event>
              <event>
                <sub_title>Suicidal ideation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1524"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="755"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="957"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="487"/>
              </event>
              <event>
                <sub_title>Suicide attempt</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1524"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="755"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="957"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="487"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Bladder prolapse</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1524"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="755"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="957"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="487"/>
              </event>
              <event>
                <sub_title>Calculus ureteric</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1524"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="755"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="957"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="487"/>
              </event>
              <event>
                <sub_title>IgA nephropathy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1524"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="755"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="957"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="487"/>
              </event>
              <event>
                <sub_title>Nephrolithiasis</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="1524"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="755"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="957"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="487"/>
              </event>
              <event>
                <sub_title>Oliguria</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1524"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="755"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="957"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="487"/>
              </event>
              <event>
                <sub_title>Renal colic</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1524"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="755"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="957"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="487"/>
              </event>
              <event>
                <sub_title>Renal cyst</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1524"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="755"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="957"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="487"/>
              </event>
              <event>
                <sub_title>Renal failure acute</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1524"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="755"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="957"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="487"/>
              </event>
              <event>
                <sub_title>Renal impairment</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1524"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="755"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="957"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="487"/>
              </event>
              <event>
                <sub_title>Renal infarct</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1524"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="755"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="957"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="487"/>
              </event>
              <event>
                <sub_title>Stress urinary incontinence</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1524"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="755"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="957"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="487"/>
              </event>
              <event>
                <sub_title>Urinary incontinence</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1524"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="755"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="957"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="487"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Adnexa uteri cyst</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1524"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="755"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="957"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="487"/>
              </event>
              <event>
                <sub_title>Cervical dysplasia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1524"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="755"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="957"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="487"/>
              </event>
              <event>
                <sub_title>Dysmenorrhoea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1524"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="755"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="957"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="487"/>
              </event>
              <event>
                <sub_title>Endometrial disorder</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1524"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="755"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="957"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="487"/>
              </event>
              <event>
                <sub_title>Endometrial hyperplasia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1524"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="755"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="957"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="487"/>
              </event>
              <event>
                <sub_title>Endometriosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1524"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="755"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="957"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="487"/>
              </event>
              <event>
                <sub_title>Menometrorrhagia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1524"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="755"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="957"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="487"/>
              </event>
              <event>
                <sub_title>Menorrhagia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="1524"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="755"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="957"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="487"/>
              </event>
              <event>
                <sub_title>Metrorrhagia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1524"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="755"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="957"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="487"/>
              </event>
              <event>
                <sub_title>Ovarian cyst</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1524"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="755"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="957"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="487"/>
              </event>
              <event>
                <sub_title>Pelvic adhesions</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1524"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="755"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="957"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="487"/>
              </event>
              <event>
                <sub_title>Polymenorrhoea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1524"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="755"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="957"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="487"/>
              </event>
              <event>
                <sub_title>Rectocele</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1524"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="755"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="957"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="487"/>
              </event>
              <event>
                <sub_title>Uterine polyp</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1524"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="755"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="957"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="487"/>
              </event>
              <event>
                <sub_title>Uterine prolapse</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1524"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="755"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="957"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="487"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Asthma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1524"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="755"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="957"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="487"/>
              </event>
              <event>
                <sub_title>Chronic obstructive pulmonary disease</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1524"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="755"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="957"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="487"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1524"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="755"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="957"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="487"/>
              </event>
              <event>
                <sub_title>Haemoptysis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1524"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="755"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="957"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="487"/>
              </event>
              <event>
                <sub_title>Lung disorder</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1524"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="755"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="957"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="487"/>
              </event>
              <event>
                <sub_title>Nasal septum deviation</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="1524"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="755"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="957"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="487"/>
              </event>
              <event>
                <sub_title>Nasal turbinate hypertrophy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1524"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="755"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="957"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="487"/>
              </event>
              <event>
                <sub_title>Pulmonary embolism</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1524"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="755"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="957"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="487"/>
              </event>
              <event>
                <sub_title>Pulmonary fibrosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1524"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="755"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="957"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="487"/>
              </event>
              <event>
                <sub_title>Sleep apnoea syndrome</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1524"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="755"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="957"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="487"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Angioedema</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1524"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="755"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="957"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="487"/>
              </event>
              <event>
                <sub_title>Cutis laxa</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1524"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="755"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="957"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="487"/>
              </event>
              <event>
                <sub_title>Eczema</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1524"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="755"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="957"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="487"/>
              </event>
              <event>
                <sub_title>Excessive skin</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1524"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="755"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="957"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="487"/>
              </event>
              <event>
                <sub_title>Panniculitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1524"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="755"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="957"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="487"/>
              </event>
              <event>
                <sub_title>Skin ulcer</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1524"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="755"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="957"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="487"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Social circumstances</title>
            <event_list>
              <event>
                <sub_title>Miscarriage of partner</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1524"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="755"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="957"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="487"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Abdominoplasty</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1524"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="755"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="957"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="487"/>
              </event>
              <event>
                <sub_title>Abortion induced</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1524"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="755"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="957"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="487"/>
              </event>
              <event>
                <sub_title>Coronary arterial stent insertion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1524"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="755"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="957"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="487"/>
              </event>
              <event>
                <sub_title>Coronary revascularisation</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="1524"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="755"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="957"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="487"/>
              </event>
              <event>
                <sub_title>Gastrectomy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1524"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="755"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="957"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="487"/>
              </event>
              <event>
                <sub_title>Gastric bypass</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1524"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="755"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="957"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="487"/>
              </event>
              <event>
                <sub_title>Heart transplant</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1524"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="755"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="957"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="487"/>
              </event>
              <event>
                <sub_title>Hip arthroplasty</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1524"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="755"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="957"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="487"/>
              </event>
              <event>
                <sub_title>Ligament operation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1524"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="755"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="957"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="487"/>
              </event>
              <event>
                <sub_title>Lipectomy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1524"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="755"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="957"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="487"/>
              </event>
              <event>
                <sub_title>Mammoplasty</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1524"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="755"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="957"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="487"/>
              </event>
              <event>
                <sub_title>Obesity surgery</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1524"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="755"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="957"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="487"/>
              </event>
              <event>
                <sub_title>Rectocele repair</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1524"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="755"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="957"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="487"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Circulatory collapse</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1524"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="755"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="957"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="487"/>
              </event>
              <event>
                <sub_title>Deep vein thrombosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1524"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="755"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="957"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="487"/>
              </event>
              <event>
                <sub_title>Embolism venous</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1524"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="755"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="957"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="487"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1524"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="755"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="957"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="487"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1524"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="755"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="957"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="487"/>
              </event>
              <event>
                <sub_title>Orthostatic hypotension</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1524"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="755"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="957"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="487"/>
              </event>
              <event>
                <sub_title>Varicophlebitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1524"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="755"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="957"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="487"/>
              </event>
              <event>
                <sub_title>Varicose vein</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1524"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="755"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="957"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="487"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA version 15.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1342" subjects_at_risk="1524"/>
                <counts group_id="E2" subjects_affected="586" subjects_at_risk="755"/>
                <counts group_id="E3" subjects_affected="843" subjects_at_risk="957"/>
                <counts group_id="E4" subjects_affected="345" subjects_at_risk="487"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" events="150" subjects_affected="112" subjects_at_risk="1524"/>
                <counts group_id="E2" events="49" subjects_affected="37" subjects_at_risk="755"/>
                <counts group_id="E3" events="79" subjects_affected="62" subjects_at_risk="957"/>
                <counts group_id="E4" events="22" subjects_affected="19" subjects_at_risk="487"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" events="137" subjects_affected="110" subjects_at_risk="1524"/>
                <counts group_id="E2" events="49" subjects_affected="40" subjects_at_risk="755"/>
                <counts group_id="E3" events="84" subjects_affected="63" subjects_at_risk="957"/>
                <counts group_id="E4" events="20" subjects_affected="18" subjects_at_risk="487"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="422" subjects_affected="333" subjects_at_risk="1524"/>
                <counts group_id="E2" events="100" subjects_affected="85" subjects_at_risk="755"/>
                <counts group_id="E3" events="255" subjects_affected="203" subjects_at_risk="957"/>
                <counts group_id="E4" events="52" subjects_affected="44" subjects_at_risk="487"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="626" subjects_affected="388" subjects_at_risk="1524"/>
                <counts group_id="E2" events="144" subjects_affected="107" subjects_at_risk="755"/>
                <counts group_id="E3" events="308" subjects_affected="201" subjects_at_risk="957"/>
                <counts group_id="E4" events="58" subjects_affected="46" subjects_at_risk="487"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" events="196" subjects_affected="156" subjects_at_risk="1524"/>
                <counts group_id="E2" events="40" subjects_affected="35" subjects_at_risk="755"/>
                <counts group_id="E3" events="121" subjects_affected="102" subjects_at_risk="957"/>
                <counts group_id="E4" events="16" subjects_affected="14" subjects_at_risk="487"/>
              </event>
              <event>
                <sub_title>Eructation</sub_title>
                <counts group_id="E1" events="96" subjects_affected="86" subjects_at_risk="1524"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="755"/>
                <counts group_id="E3" events="52" subjects_affected="38" subjects_at_risk="957"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="487"/>
              </event>
              <event>
                <sub_title>Flatulence</sub_title>
                <counts group_id="E1" events="94" subjects_affected="81" subjects_at_risk="1524"/>
                <counts group_id="E2" events="25" subjects_affected="22" subjects_at_risk="755"/>
                <counts group_id="E3" events="35" subjects_affected="29" subjects_at_risk="957"/>
                <counts group_id="E4" events="17" subjects_affected="15" subjects_at_risk="487"/>
              </event>
              <event>
                <sub_title>Gastrooesophageal reflux disease</sub_title>
                <counts group_id="E1" events="112" subjects_affected="101" subjects_at_risk="1524"/>
                <counts group_id="E2" events="19" subjects_affected="18" subjects_at_risk="755"/>
                <counts group_id="E3" events="50" subjects_affected="47" subjects_at_risk="957"/>
                <counts group_id="E4" events="8" subjects_affected="8" subjects_at_risk="487"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="974" subjects_affected="622" subjects_at_risk="1524"/>
                <counts group_id="E2" events="170" subjects_affected="128" subjects_at_risk="755"/>
                <counts group_id="E3" events="616" subjects_affected="418" subjects_at_risk="957"/>
                <counts group_id="E4" events="96" subjects_affected="78" subjects_at_risk="487"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="476" subjects_affected="300" subjects_at_risk="1524"/>
                <counts group_id="E2" events="55" subjects_affected="42" subjects_at_risk="755"/>
                <counts group_id="E3" events="267" subjects_affected="172" subjects_at_risk="957"/>
                <counts group_id="E4" events="29" subjects_affected="25" subjects_at_risk="487"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="190" subjects_affected="154" subjects_at_risk="1524"/>
                <counts group_id="E2" events="67" subjects_affected="58" subjects_at_risk="755"/>
                <counts group_id="E3" events="89" subjects_affected="79" subjects_at_risk="957"/>
                <counts group_id="E4" events="31" subjects_affected="27" subjects_at_risk="487"/>
              </event>
              <event>
                <sub_title>Injection site haematoma</sub_title>
                <counts group_id="E1" events="102" subjects_affected="91" subjects_at_risk="1524"/>
                <counts group_id="E2" events="69" subjects_affected="61" subjects_at_risk="755"/>
                <counts group_id="E3" events="68" subjects_affected="64" subjects_at_risk="957"/>
                <counts group_id="E4" events="45" subjects_affected="42" subjects_at_risk="487"/>
              </event>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" events="60" subjects_affected="53" subjects_at_risk="1524"/>
                <counts group_id="E2" events="58" subjects_affected="47" subjects_at_risk="755"/>
                <counts group_id="E3" events="25" subjects_affected="22" subjects_at_risk="957"/>
                <counts group_id="E4" events="7" subjects_affected="6" subjects_at_risk="487"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" events="139" subjects_affected="114" subjects_at_risk="1524"/>
                <counts group_id="E2" events="80" subjects_affected="62" subjects_at_risk="755"/>
                <counts group_id="E3" events="41" subjects_affected="35" subjects_at_risk="957"/>
                <counts group_id="E4" events="27" subjects_affected="26" subjects_at_risk="487"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" events="171" subjects_affected="138" subjects_at_risk="1524"/>
                <counts group_id="E2" events="53" subjects_affected="46" subjects_at_risk="755"/>
                <counts group_id="E3" events="53" subjects_affected="48" subjects_at_risk="957"/>
                <counts group_id="E4" events="32" subjects_affected="24" subjects_at_risk="487"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" events="249" subjects_affected="181" subjects_at_risk="1524"/>
                <counts group_id="E2" events="123" subjects_affected="80" subjects_at_risk="755"/>
                <counts group_id="E3" events="84" subjects_affected="65" subjects_at_risk="957"/>
                <counts group_id="E4" events="37" subjects_affected="26" subjects_at_risk="487"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" events="764" subjects_affected="404" subjects_at_risk="1524"/>
                <counts group_id="E2" events="408" subjects_affected="210" subjects_at_risk="755"/>
                <counts group_id="E3" events="290" subjects_affected="193" subjects_at_risk="957"/>
                <counts group_id="E4" events="166" subjects_affected="110" subjects_at_risk="487"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" events="174" subjects_affected="129" subjects_at_risk="1524"/>
                <counts group_id="E2" events="111" subjects_affected="65" subjects_at_risk="755"/>
                <counts group_id="E3" events="99" subjects_affected="84" subjects_at_risk="957"/>
                <counts group_id="E4" events="47" subjects_affected="35" subjects_at_risk="487"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="389" subjects_affected="236" subjects_at_risk="1524"/>
                <counts group_id="E2" events="213" subjects_affected="120" subjects_at_risk="755"/>
                <counts group_id="E3" events="122" subjects_affected="101" subjects_at_risk="957"/>
                <counts group_id="E4" events="68" subjects_affected="54" subjects_at_risk="487"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" events="176" subjects_affected="123" subjects_at_risk="1524"/>
                <counts group_id="E2" events="62" subjects_affected="43" subjects_at_risk="755"/>
                <counts group_id="E3" events="60" subjects_affected="48" subjects_at_risk="957"/>
                <counts group_id="E4" events="19" subjects_affected="15" subjects_at_risk="487"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Lipase increased</sub_title>
                <counts group_id="E1" events="207" subjects_affected="145" subjects_at_risk="1524"/>
                <counts group_id="E2" events="26" subjects_affected="24" subjects_at_risk="755"/>
                <counts group_id="E3" events="41" subjects_affected="35" subjects_at_risk="957"/>
                <counts group_id="E4" events="10" subjects_affected="10" subjects_at_risk="487"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Decreased appetite</sub_title>
                <counts group_id="E1" events="181" subjects_affected="169" subjects_at_risk="1524"/>
                <counts group_id="E2" events="28" subjects_affected="27" subjects_at_risk="755"/>
                <counts group_id="E3" events="111" subjects_affected="102" subjects_at_risk="957"/>
                <counts group_id="E4" events="17" subjects_affected="16" subjects_at_risk="487"/>
              </event>
              <event>
                <sub_title>Hypoglycaemia</sub_title>
                <counts group_id="E1" events="637" subjects_affected="295" subjects_at_risk="1524"/>
                <counts group_id="E2" events="52" subjects_affected="35" subjects_at_risk="755"/>
                <counts group_id="E3" events="302" subjects_affected="176" subjects_at_risk="957"/>
                <counts group_id="E4" events="37" subjects_affected="29" subjects_at_risk="487"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" events="231" subjects_affected="186" subjects_at_risk="1524"/>
                <counts group_id="E2" events="134" subjects_affected="97" subjects_at_risk="755"/>
                <counts group_id="E3" events="41" subjects_affected="38" subjects_at_risk="957"/>
                <counts group_id="E4" events="29" subjects_affected="23" subjects_at_risk="487"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" events="283" subjects_affected="198" subjects_at_risk="1524"/>
                <counts group_id="E2" events="159" subjects_affected="118" subjects_at_risk="755"/>
                <counts group_id="E3" events="97" subjects_affected="77" subjects_at_risk="957"/>
                <counts group_id="E4" events="50" subjects_affected="41" subjects_at_risk="487"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" events="127" subjects_affected="108" subjects_at_risk="1524"/>
                <counts group_id="E2" events="64" subjects_affected="54" subjects_at_risk="755"/>
                <counts group_id="E3" events="27" subjects_affected="25" subjects_at_risk="957"/>
                <counts group_id="E4" events="24" subjects_affected="22" subjects_at_risk="487"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="197" subjects_affected="149" subjects_at_risk="1524"/>
                <counts group_id="E2" events="73" subjects_affected="55" subjects_at_risk="755"/>
                <counts group_id="E3" events="81" subjects_affected="67" subjects_at_risk="957"/>
                <counts group_id="E4" events="20" subjects_affected="19" subjects_at_risk="487"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="432" subjects_affected="273" subjects_at_risk="1524"/>
                <counts group_id="E2" events="223" subjects_affected="124" subjects_at_risk="755"/>
                <counts group_id="E3" events="178" subjects_affected="127" subjects_at_risk="957"/>
                <counts group_id="E4" events="80" subjects_affected="58" subjects_at_risk="487"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="133" subjects_affected="112" subjects_at_risk="1524"/>
                <counts group_id="E2" events="87" subjects_affected="60" subjects_at_risk="755"/>
                <counts group_id="E3" events="35" subjects_affected="34" subjects_at_risk="957"/>
                <counts group_id="E4" events="23" subjects_affected="22" subjects_at_risk="487"/>
              </event>
              <event>
                <sub_title>Oropharyngeal pain</sub_title>
                <counts group_id="E1" events="81" subjects_affected="74" subjects_at_risk="1524"/>
                <counts group_id="E2" events="52" subjects_affected="44" subjects_at_risk="755"/>
                <counts group_id="E3" events="34" subjects_affected="31" subjects_at_risk="957"/>
                <counts group_id="E4" events="22" subjects_affected="21" subjects_at_risk="487"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="86" subjects_affected="74" subjects_at_risk="1524"/>
                <counts group_id="E2" events="58" subjects_affected="48" subjects_at_risk="755"/>
                <counts group_id="E3" events="23" subjects_affected="22" subjects_at_risk="957"/>
                <counts group_id="E4" events="13" subjects_affected="13" subjects_at_risk="487"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>When the primary results are available, Novo Nordisk plans to discuss the interpretation of these with the principal Investigator, but reserves the right to release results that may impact Novo Nordisk financial expectations (e.g. a press release directly to the public or similar) without prior consultation with the remaining participating Investigators. Novo Nordisk reserves the right not to release data until specified milestones, e.g. a clinical trial report is available.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Public Access to Clinical Trials</name_or_title>
      <organization>Novo Nordisk A/S</organization>
      <email>clinicaltrials@novonordisk.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

